<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
	<title>Factiva</title>
<style type="text/css">body{margin:0;}form{margin:0;padding:0;}.icon a{display:block;}.nlFooter .icon a{display:inline-block!important;top:3px;}.icon span{display:none;}#postProcessingNav .icon{margin-right:15px;}#viewSelected,#viewSelected a{width:22px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:0 -212px;}#rtf,#rtf a{width:24px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-23px -212px;}#email,#email a{width:19px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-48px -212px;}#print,#print a{width:18px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-68px -212px;}#save,#save a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-87px -212px;}#briefcase,#briefcase a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-105px -212px;}#csv,#csv a{width:27px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-125px -212px;}.modalNavGreen{background-color:#9C0;}.modalNavGreen td{vertical-align:middle;height:22px;padding:0 5px;white-space:nowrap;}td.modalTabGreen{height:18px;padding:0 10px 0 5px;vertical-align:bottom;background : url('../img/edgew.gif?42.27.0')  no-repeat right bottom;}td.modalTabWhite{background-color:#fff;height:18px;width:100%;padding:0;}span.tabTitle{color:#333;font-weight:bold;}a.supportLink{color:#55B0EB!important;float:right;vertical-align:top;text-decoration:none;}a.supportLink #helpIconCont{vertical-align:middle;width:19px;height:19px;}.modalSubTitle{position:relative;float:left;top:2px;margin-left:5px;}.modalTitle{position:relative;float:left;}.pipe{font-weight:normal;font-size:10px;color:#B5BACE;}span.checked{color:#A52A2A;font-weight:bold;}DIV.modalForm{background-color:#EEE;margin:10px 10px;}DIV.modalGgoup{width:auto;padding:10px;background-color:#D9DBE8;border-bottom:solid 1px #fff;border-top:solid 1px #fff;}DIV.modalGroupSpace{padding:3px;}.modalContainer{background-color:#EEE;padding:0 10px;}p.button-row{text-align:right;padding:0 10px;}.folderOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -135px -110px transparent;width:21px;height:16px;margin-right:8px;float:left;}.folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -134px -94px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupOpen{padding:3px 0 3px 25px;background : url('../img/group_open.gif?42.27.0')  no-repeat left center;}.groupClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -85px -110px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupUnknown .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -182px -94px transparent;width:18px;height:14px;margin-right:11px;float:left;}.sharedOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -153px -94px transparent;width:26px;height:15px;margin-right:3px;float:left;}.sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -104px -110px transparent;width:26px;height:15px;margin-right:3px;float:left;}.folderTrigger .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -110px;width:16px;height:16px;margin-right:13px;float:left;}.folderClosed .itemText,.folderOpen .itemText,.groupClosed .itemText,.groupUnknown .itemText,.sharedOpen .itemText,.sharedClosed .itemText,.folderTrigger .itemText{margin-top:2px;float:left;}.folderClosed,.folderOpen,.groupClosed,.groupUnknown,.sharedOpen,.sharedClosed,.folderTrigger{margin:1px 0;}#folderDD .folderOpen,#folderList .folderOpen{padding-left:3px;}#folderDD .folderClosed,#folderList .folderClosed{padding-left:3px;height:inherit!important;}#folderDD .groupOpen,#folderList .groupOpen{padding-left:3px;}#folderDD .groupClosed,#folderList .groupClosed{padding-left:3px;}#folderDD .groupUnknown,#folderList .groupUnknown{padding-left:3px;}#folderDD .sharedOpen,#folderList .sharedOpen{padding-left:3px;}#folderDD .sharedClosed,#folderList .sharedClosed{padding-left:3px;}#folderDD .folderTrigger,#folderList .folderTrigger{padding-left:3px;}a.folderLink{color:#309;text-decoration:none;}a.folderLink:hover{color:#309;text-decoration:underline;}.onlineUBody{font-style:normal;font-weight:normal;}.padder{text-align:left;background-color:#DCDADA;}.spanheader{float:left;font-weight:bold;width:190px;}.spanheader2{float:left;text-align:right;font-weight:normal;width:auto;}.bol{font-weight:bold;}.padLks{width:100%;text-align:right;}table.usageHeader{background-color:#ffc;margin-top:.5em;padding:0 .5em;border:1px solid black;width:100%;}table.usageHeader th{text-align:left;}table.usageItems{background-color:#eee;border-bottom:2px solid #ccc;border-left:2px solid #ccc;border-right:2px solid #ccc;border-top:2px solid #ccc;width:100%;}table.usageItems thead tr td{background-color:#eee;font-weight:bold;padding-left:5px;color:#000;padding-bottom:0;padding-top:0;text-align:left;}table.usageItems tr,table.usageItems td{background-color:#fff;padding:15px;padding-bottom:0;padding-top:0;text-align:right;}table.usageItems td.first{text-align:left;width:33%;}table.usageItems th{text-align:right;font-weight:bold;}table.usageItems th.first{text-align:left;}table.usageItems tr.even td{background-color:#ffc;}table.usageItems th.whatIf,table.usageItems td.whatIf{color:#060;}table.usageItems tr.footer td{font-weight:bold;background-color:#eee;text-align:right;}table.usageItems tfoot td{font-weight:bold;background-color:#eee;text-align:right;color:#C06;}.APDATA{background-color:#ccc;margin-bottom:0;font-weight:bold;padding:4px;text-align:left;color:#000;}div.last{text-align:right;font-weight:bold;}.bold{font-weight:bold;vertical-align:top;white-space:nowrap;}.greenTable{border:1px solid #BD5;width:100%;}.applyBackGround{background-color:#BD5;}A.simpleLink{color:#000!important;background-color:transparent!important;font-weight:bold!important;}#narrowicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -216px -62px;}#wideicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -232px -62px;}td.nrCol div a{display:inline-block;height:5px;margin:5px 0 0 5px;width:10px;overflow:hidden;}#uparrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -67px;}#downarrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -60px;}input.majorButton{background-color:#9C0;}input.minorButton{background-color:#CCC;}.errMsg{color:Red;}div.divFactivaException,div.divFactivaException table{background-color:#CCC;}div.divFactivaException table.subTable{background-color:#999;}div.loadingDiv{padding:10px 10px;text-align:center;font-weight:normal;}.colorLinks{color:Blue;}#listenArticle_link{margin:0 0 0 20px;}#cr_span{position:relative;float:left;clear:both;}#crIcon{position:relative;vertical-align:text-top;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -220px -21px;}.relInfoDiv{position:absolute;visibility:hidden;z-index:10000;border:solid 2px #999;border-top-color:#DEDEE9;border-left-color:#DEDEE9;background-color:#FBFBFE;width:450px;overflow:auto;height:auto;}.relInfo div.relInfoHeader{color:#666;padding:5px;border-bottom:solid 1px #DEDEE9;text-align:center;font-weight:bold;}.relInfo div.relInfoSubHeader{padding:5px;font-weight:bold;}.relInfo div.newLine{padding:0 5px 5px 5px;}.relInfo div.newLine a,.relInfo div.newLine a:visited{color:#54559B;text-decoration:none;}.relInfo div.newLine a:hover{text-decoration:underline;}#relInfoBody{padding:10px;}.popupCnt{background-color:#F2F3FB;position:absolute;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}.popupHdr{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;}div.floatRight{float:right;clear:right;}div.floatLeft{float:left;clear:left;}.popupHdr a.close{color:#309;text-decoration:none;}.popupHdr a.close:hover{color:#309;text-decoration:underline;}.dedupDiv{display:inline;white-space:nowrap;}.dedupDropdown{display:inline-block;white-space:nowrap;vertical-align:top;background:#dee3f1;color:#333;padding:0 0 3px 0;cursor:pointer;border:1px solid;border-top-color:#e9eefb;border-right-color:#99a3c3;border-bottom-color:#99a3c3;border-left-color:#e9eefb;}.dedupDropdown:hover{border-color:#B5BACE;text-decoration:none;}.dedupDropdown span{float:left;margin-left:4px;}.dedupDropdown .ddArrow{display:block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -244px -195px;width:18px;height:14px;}.newIcon{vertical-align:middle;border:none;}.dedupMenu{display:none;position:absolute;z-index:10000;border:1px solid #999;background-color:#f5f6fb;width:360px;}.dedupMenu ul{list-style:none;margin:0;padding:0;text-align:left;}.dedupMenu li a{margin:0;padding:5px;cursor:pointer;display:block;text-decoration:none;outline:none;color:#000;white-space:normal;}.dedupMenu li a:hover{background-color:#C3C4FC;text-decoration:none;}.dedupMenu li.dedupSelected a{background-color:#DFDFFC!important;}#dedupState{font-weight:bold;vertical-align:top;}#dedupState2{font-weight:bold;}#hlpBox{background-color:#F2F3FB;position:absolute;width:400px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#ShowLatestBox{background-color:#F2F3FB;position:absolute;width:500px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#hlpBoxShim,#dedupMenuShim{position:absolute;visibility:hidden;left:0;top:0;}.srchHelp{padding:10px;}.srchHelp DIV{padding-bottom:5px;}.srchHelp OL,.srchHelp UL{margin-top:2px;}.srchHelp .OL{list-style-type:decimal;}.hplTable{padding:10px;overflow:hidden;}.hplTable table td{white-space:normal;}.BoxTL{padding-left:0;margin-right:1px;}.BoxTL .BoxTR{background-color:#E2E6F3;border:1px solid #8C92B1;padding-top:6px;}.BoxTL .BoxBR{padding-right:6px;}.BoxTL .BoxBL{padding:0 0 6px 6px;}input.majorBtn{background-color:#9C0;}.inputAlign{vertical-align:middle;}.xDialog{position:absolute;top:0;left:0;padding:1px;}.xDialog .header{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;color:#333;background:#FFF;font-weight:bold;background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x right bottom;}.xDialog .header .close{position:absolute;display:block;top:3px;right:3px;overflow:hidden;}.xDialog .footer{position:relative;background-color:#FFF;padding:3px;}.xDialog .body{position:relative;position:relative;border-top:solid 1px #CCC;background-color:#FFF;height:auto;width:100%;}.xDialog .body .loading{background-color:#FFF;padding:3px;color:#333;font-weight:bold;}.PopupBackground{position:absolute;left:0;top:0;background:#A5A5A5;filter:alpha(opacity=60);opacity:.60;z-index:9999;}#appendAJAX{position:absolute;top:0;left:0;z-index:1000;}.mcemailPopupDialog{position:absolute;top:0;left:0;padding:1px;background : url('../img/mcemailpopupbg.png?42.27.0')  no-repeat left top;}.mobileCookieEmailDiv{position:relative;width:auto;display:block;padding:10px;height:150px;}.mobileCookieEmailDivPlaceholder{position:relative;width:auto;}#mobileCookieEmailDivPopup .buttons .btn{position:static!important;}#mobileCookieEmailDivHeader{font-weight:bold;}#mobileCookieEmailDivMsg3{position:relative;padding:10px;margin-left:70%;white-space:nowrap!important;}#mobileCookieEmailDivPopup{position:relative;margin-right:150px;}#mobileCookieEmailOnClickDiv{display:none;position:relative;vertical-align:top;margin-right:100px;}.odeMessage{color:#CE009C;font-weight:bold;}.edTableRowSeperator{background-color:#CCC;padding-top:1px;padding-bottom:1px;}.edLink{text-decoration:none;color:#648CAF;}.edLink:hover{text-decoration:none;color:#648CAF;}.edLinkPipe{font-family:Arial,Helvetica,sans-serif;color:#999;text-decoration:none;font-weight:normal;}.edTitleBold{font-weight:bold;}.edDescriptionSeperator{background-color:#999;padding-top:2px;padding-bottom:2px;}#translateArticleDiv{display:inline;}#translateArticleDiv a{color:#7C7EC9;text-decoration:none;}#translateArticleDiv img{padding-right:3px;margin-bottom:-2px;border:0;}#translateLanguagesDiv{display:none;position:absolute;border:solid 1px #999;z-index:1;}#translateLanguagesDiv.visiblek{display:inline;}#translateLanguagesDiv ul{list-style-type:none;list-style-position:outside;list-style-image:none;}.languagesDiv{background-color:#FBFBFE;border-color:#DEDEE9 #999999 #999 #DEDEE9;border-style:solid;border-width:2px;height:auto;overflow:auto;position:absolute;visibility:hidden;width:250px;z-index:10000;}#translateLanguagesDiv a,.languagesDiv #relInfoBody a{color:#000;background-color:#F0F0F0;padding-left:5px;padding-right:5px;display:block;}#translateLanguagesDiv a:hover,.languagesDiv #relInfoBody a:hover{background-color:#CCC;}.smb{height:44px!important;}#gl-navTopLeft-ADVISOR{position:absolute;top:0;left:0;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -21px;width:215px;white-space:nowrap;}#djr1{position:absolute;right:5px;top:46px;width:183px;height:22px;background:#fff url(../img/djr-shadow.gif) no-repeat right top;z-index:9997;}#gl-navTopRightUl li#mbrightddtbm3 DIV{width:220px;}#gl-navTopRightUl li#mbrightddtbm3 ul,#gl-navTopRightUl li#mbrightddtbm3 ul li,#gl-navTopRightUl li#mbrightddtbm3 ul a{width:148px;width:200px;}#gl-navBottomMiddle ul li ul li div,#gl-navBottomMiddle ul li ul li div span{float:left;float:none;}#gl-navBottom div.gl-navBottomHolder{height:1px;font-size:.1em;}#gl-navBottomMiddle li.subMenuSpcr div{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -130px -94px;height:13px;width:1px;margin:0 2px;}#gl-navBottomMiddle li.subMenuSpcr div.EUPipe3{background:none;padding-right:6px;width:0;margin:0;}#gl-navBottomMiddle SPAN.fceSubMenuLabel{padding-left:5px;}#supportGreenLink{background : url('../img/dotcomgreen2.jpg?42.27.0')  no-repeat right top;padding:0 0 5px 0;height:19px;}#supportGreenLink a{color:#369;font-weight:bold;text-decoration:none;background : url('../img/dotcomgreen1.jpg?42.27.0')  no-repeat left top;padding:1px 6px 6px 6px;height:19px;}#supportGreenLink a:hover{color:#369;text-decoration:none;font-weight:bold;}td.supportGreenLink{vertical-align:top;height:22px;padding:0 5px;white-space:nowrap;padding-top:2px;}.feedBack{font-family:Arial,Helvetica,sans-serif;}.footerBG #djInsiderCtrl{display:inline;}#LinkFormExElem{display:none;}#NavAdPlaceHolder{position:absolute;top:6px;right:5px;height:18px;width:155px;font-weight:bold;text-align:center;vertical-align:middle;padding-top:1px;font-family:Arial,Helvetica,sans-serif;}#NavAdPlaceHolder a{color:#005596;}#uiVersion{color:#FFF;}#djimenu{margin:1px 0 0 0;padding:0;height:16px;}#djimenu img{border:none;vertical-align:top;margin-top:-2px;padding-right:8px;}#djimenu a{color:#000;font-weight:bold;text-decoration:none;height:16px;margin:0;padding:0 8px 0 0;font-family:Arial,Helvetica,sans-serif;}.mrm #gl-navBottom{background : url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x scroll 0 0 transparent!important;height:33px;padding:0 0 30px;position:relative;}.mrm #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -105px transparent!important;width:300px!important;}.mrm #gl-navBottom{background : url('../img/sprite_bg_x_801px.jpg?42.27.0')  repeat-x top left;background-position:0 0;}.insight #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -135px transparent!important;width:300px!important;background-color:#fff;}html>body #tblinkiff a{padding-top:4px;}.adContainer{position:relative;display:none;padding:0 0 10px 5px;}.adContainer_Login{position:static;display:none;padding:0 0 10px 5px;}.adContainer_Article{position:relative;display:none;padding:0 0 0 5px;}.article_Adwrapper{width:50%;float:right;height:125px;}.adHeader{float:right;}.adBody{clear:both;}a.helpLinkStyle,a.helpLinkStyle:visited{color:#55B0EB;text-decoration:none;cursor:pointer;}a.helpLinkUnderLine,a.helpLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle,a.tsLinkStyle:visited{color:#800080!important;text-decoration:none;}a.tsLinkUnderLine,a.tsLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle:hover{color:#800080!important;text-decoration:underline!important;}div.dbgViewXmlFormat{background-color:#000;color:#32cd32;}.brwsLbl{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -250px -73px;}.lkpBar .lkpBtn.wsjLkpBtn{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -241px -21px;}#fiiInstruction{background : url('../img/sprite_bg_x_1px.gif?42.27.0')  repeat-x top left;}#fiiInstruction TD.pnlsTtl div.separator{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -132px -94px;}.tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -40px transparent;}.tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -20px transparent;}.firstDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -323px transparent;*display:inline-block;*position:relative;*top:2px;}.secondDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll -2px -343px transparent;}.scheduledDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -382px transparent;}.continuousDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -363px transparent;}.onlineDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -683px transparent;}.emptyDel{background:none;}.xmlLink.xmlLinkWithIcon,.xmlLink.xmlLinkWithIcon a:hover{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -400px transparent!important;}.xmlLinkWithIcon{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -340px -3px transparent;}.xmlLinkWithIcon:hover{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -338px -26px transparent;}html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,font,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}.sbTable td{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}body{line-height:1;background-color:#FFF!important;}ol,ul{list-style:none;}blockquote,q{quotes:none;}blockquote:before,blockquote:after,q:before,q:after{content:'';content:none;}select{font-size:1em;padding:1px;}:focus{outline:0;}ins{text-decoration:none;}del{text-decoration:line-through;}table{border-collapse:collapse;border-spacing:0;}body{text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:72.5%;line-height:normal;color:#666;}div,table,td{font-size:1em;}h1,h2,h3,h4,h5,h6{font-size:1em;}p img.left{float:left;margin:1.5em 1.5em 1.5em 0;padding:0;}p img.right{float:right;margin:1.5em 0 1.5em 1.5em;}a{color:#55b0eb;text-decoration:none;}a:focus,a:hover{color:#666;text-decoration:none;}body{margin:0;}#contentWrapper{padding:0 15px;}.WorkSpace .wsList{padding:0!important;}#gl-navContainer{z-index:800;position:relative;width:98%;margin-left:10px;}#gl-navTop{height:33px;background-image:none;background-color:#fff;z-index:810;}#gl-navTop table{height:33px;vertical-align:middle;background-color:#fff;}#gl-navTop table td{vertical-align:middle;}#gl-navTop #gl-navTopLeft{vertical-align:top;padding-left:15px;}#gl-navTop #gl-navTopLeft h1{width:123px;height:20px;font-size:.1em;text-indent:-9999px;background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat 0 -209px #fff;margin:0;padding:0;position:relative;top:6px;}#gl-navTop #gl-navTopRight{padding-right:15px;}#gl-navTopRightUl{float:right;z-index:9997;margin:0;}#gl-navTopRightUl li.userNavItem{float:left;height:12px;position:relative;line-height:12px;padding:0 7px;border-right:1px solid #ccc;z-index:9998;}#gl-navTopRightUl li#mbrightddtbm241{border:none;}#gl-navTopRightUl li a{display:block;line-height:10px;margin-bottom:1px;}#gl-navTopRightUl li a:hover,#gl-navTopRightUl li.over a{color:#55b0eb;}#gl-navTopRightUl li#mbrightddtbm1,#gl-navTopRightUl li#mbrightddtbm0{padding-right:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -4px;}#gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat left -64px;}#gl-navTopRightUl li.over{background-color:#333;}#gl-navTopRightUl li#mbrightddtbm241{padding-right:6px;}#gl-navTopMiddle a,#gl-navTopRightUl a{color:#666;margin:0;}#gl-navTopRightUl #myDJFmenu a{padding-left:12px;}#gl-navContainer a,#gl-navContainer a:hover{color:#4D5926;text-decoration:none;}#gl-navTopRightUl #mbrightddtbm0 div,#gl-navTopRightUl li .settingsToolsDrop{position:absolute;top:12px;right:0;background-color:#333;padding:5px;border:1px solid #000;z-index:9999;}#gl-navTopRightUl li .settingsToolsDrop{width:450px;_width:452px;}#gl-navTopRightUl li div{display:none;}#gl-navTopRightUl li.over div{display:block;}#gl-navTopRightUl li .settingsToolsDrop div{float:left;width:150px;}#gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{color:#55b0eb;font:normal 1.1em Arial,Helvetica,sans-serif;line-height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 0;margin:0;padding-left:20px;}#gl-navTopRightUl li .settingsToolsDrop div .Tools{background-position:0 -160px;}#gl-navTopRightUl li .settingsToolsDrop div .Lists{background-position:0 -200px;}#gl-navTopRightUl li .settingsToolsDrop div .Language{background-position:0 -240px;}#gl-navTopRightUl li .settingsToolsDrop div .Account{background-position:0 -220px;}#gl-navTopRightUl li .settingsToolsDrop div .Settings{background-position:0 -180px;}#gl-navTopRightUl #mbrightddtbm0 div ul,#gl-navTopRightUl li .settingsToolsDrop div ul{background:none;padding:0;}#gl-navTopRightUl #mbrightddtbm0 div ul{width:250px;}#gl-navTopRightUl li .settingsToolsDrop div ul{margin-bottom:10px;}#gl-navTopRightUl #mbrightddtbm0 div ul li,#gl-navTopRightUl li .settingsToolsDrop div ul li{background:none;border:none;}#gl-navTopRightUl #mbrightddtbm0 div ul li a,#gl-navTopRightUl li .settingsToolsDrop div ul li a{display:block;color:#fff;background:none;padding:3px 20px 3px 10px;white-space:normal;}#gl-navTopRightUl #mbrightddtbm0 div ul li a:hover,#gl-navTopRightUl li .settingsToolsDrop div ul li a:hover{background:none;border:none;color:#333;background-color:#f4f4f4;}#gl-navBottomMiddle ul li.selected ul.selected li.subMenuSpcr{display:none;}#gl-navBottom{height:33px;position:relative;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;padding:0 0 30px;}#gl-navBottomMiddle{height:33px;width:100%!important;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat right -132px;}#gl-navBottomMiddle ul#menulist{height:33px;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -99px;padding:0;margin:0;}#gl-navBottomMiddle ul li{float:left;margin:0;padding:0 0 0 15px;cursor:pointer;}#gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 0;}#gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -33px;}#gl-navBottomMiddle ul li a{display:block;float:none;color:#afafaf;cursor:pointer;line-height:33px;background:none;outline:none;padding:0 10px 0 0;}#gl-navBottomMiddle ul li a:hover{color:#afafaf;}#gl-navBottomMiddle ul li.selected a{font-weight:normal;color:#fff;background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;cursor:pointer;}#gl-navBottomMiddle ul li.selected a:hover{color:#fff;}#gl-navBottomMiddle ul li ul{display:none;}#gl-navBottomMiddle ul li.selected ul.selected{display:block;min-width:600px;height:30px;position:absolute;top:33px;left:0;padding:0 15px;cursor:default;}* html #gl-navBottomMiddle ul li.selected ul.selected{width:750px;}#gl-navBottomMiddle ul li.selected ul.selected li{float:left;display:inline-block;height:30px;margin-right:10px;padding:0;white-space:nowrap;}#gl-navBottomMiddle ul li.selected ul.selected li a{display:inline;height:30px;color:#666;line-height:30px;background:none;padding:0;cursor:pointer;}#gl-navBottomMiddle ul li.selected ul.selected li a:hover{color:#55b0eb;}#gl-navBottomMiddle ul li.selected ul.selected li a.selectedSubMenu{color:#55b0eb;font-weight:normal!important;}#mentionedLabel1{z-index:710;}#mentionedLabel1 div{z-index:725;}#pageFooter{background: transparent url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;padding:10px 15px 5px;height:10px;}#pageFooter .shadowL,#pageFooter .shadowR{display:none!important;}.footerBrand{width:101px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -40px;margin:0;}.ftright{width:66px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -80px;}#pageFooter .copyright{color:#666;line-height:normal;}.footerBG .feedBack,.feedBack:hover,.footerBG .whatsNew,.whatsNew:hover,.footerBG .privacy,.privacy:hover,.footerBG .djinsider,.djinsider:hover,.footerBG #djInsiderCtrl a,.footerBG #djInsiderCtrl a:hover{color:#666!important;line-height:normal!important;border-right:1px solid #666!important;padding:0 5px!important;}.footerBG .privacy,.privacy:hover{margin-right:10px;border:none;}.footerBG .pipe{display:none;}.simpleSearchBottom:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.simpleSearchBottom,.clearFix{zoom:1;}* html .simpleSearchBottom,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.ac_input{font:Arial,Helvetica,sans-serif!important;}.ssTable{width:100%;}.ssTable td{vertical-align:top;}.ssTable .shadowLeft{width:10px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 0;}.ssTable .ssTextBox{height:26px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  repeat-x 0 -56px;}.ssTable .shadowRight{width:12px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 -28px;}.ssTable .ssTextBox input{width:100%;mn-height:17px;line-height:13px;background:none;border:none;margin:0;padding-top:6px;outline:none;}.simpleSearchBottom{padding:5px 0;}.simpleSearchSelectSource{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;margin-right:10px;}.simpleSearchSelectDate{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit{float:right;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit ul.buttons{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.columnsCntr ul{list-style:none;}.columnsCntr #LtCol,.columnsCntr #MdCol,.columnsCntr #RtCol{float:left;width:300px;margin-right:30px;}.columnsCntr #RtCol{width:300px;}wHeaderBar{margin-bottom:10px;}.wHeaderTtl span{display:block;color:#007ec5;font:bold 1.6em Arial,Helvetica,sans-serif;padding:0 5px;}.wBodyMax ul li{padding-bottom:3px;}.wBodyMax ul li a{display:block;color:#333;padding:0 5px;}.wBodyMax ul li a:hover{background-color:#f0f0f0;}#dateAndDupRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}#dateAndDupRow,.clearFix{zoom:1;}* html #dateAndDupRow,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.sbTable{width:100%;}.sbTable .shadowTopLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px 0;}.sbTable .shadowTopMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite2.png?42.27.0')  repeat-x 0 -33px;}.sbTable .shadowTopRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -12px;}.sbTable .shadowLeft{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y 0 0;}.sbTable .sbTextBox{background-color:#fff;}.sbTable .shadowRight{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y -12px 0;}.sbTable .shadowBotLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -36px;}.sbTable .shadowBotMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.png?42.27.0')  repeat-x 0 -45px;}.sbTable .shadowBotRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -24px;}.sbTable .sbTextBox .searchBuilder{width:100%;background:none;border:none;margin:0;outline:none;font:Arial,Helvetica,sans-serif!important;}.blur{color:#ccc;}.txtWrapperDiv{background:#fff url(../img/facelift/shadowRepeating.png) repeat-x 0 bottom;}.txtWrapperDiv div.shadowL,.txtWrapperDiv div.shadowR{height:20px;}.txtWrapperDiv div.shadowL{background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}.txtWrapperDiv div.shadowR{background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat right 0;}.searchFormDiv td input{width:80%;}.searchToggleSwitchWrap{padding:0 15px;}.freeTextSwitch{border-bottom:1px solid #fff;border-top:1px solid #fff;}.searchFormSwitch{border-bottom:1px solid #fff;}.freeTextSwitch a,.searchFormSwitch a{display:block;color:#666;text-decoration:none;padding:5px 10px;}.freeTextSwitch a:hover,.searchFormSwitch a:hover{text-decoration:none;}.selected a{color:#55b0eb;cursor:default;}.selected a:hover{cursor:default;}.searchToggleBoxWrap{background-color:#F0F0F0;border:1px solid #E7E7E7;padding:10px 0 10px 0;}.searchToggleBoxWrap .col1{width:170px;}.searchToggleBoxWrap .col2{margin-left:170px;float:none!important;}#textAndConceptContainer{position:relative;padding:0 10px 0 0;}.sbTableWrap a{display:block;position:absolute;left:-249px;top:60px;color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.sbTableWrap a:hover{color:#55b0eb;}.exampleLink{display:none;padding:10px 0 0 11px;}.exampleLink a{color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.fcsclose,.fcsopen{display:block;height:20px;font-weight:bold;line-height:20px;background-image : url('../img/facelift/facelift-icon-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;padding:0 0 0 20px;}.fcsclose{background-position:0 -119px;}.fcsopen{background-position:0 -140px;}#dateAndDupRow{padding:10px 0 0 0;}#dateAndDupRow .sbFld{float:left;margin-right:20px;padding:0;}#dateAndDupRow #datePnl{float:left;top:-5px;}.sbFld label{margin:0 5px;}.pnlTab{cursor:pointer;padding:0 5px 0 20px;width:175px;vertical-align:top;height:22px;}.pnlTabOpen{cursor:pointer;width:175px;padding:0 5px 0 20px;vertical-align:top;}.pnlTab .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -20px;}.pnlTabOpen .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -40px;}.pnlTrTab .pnlLst{border-bottom:1px solid #f0f0f0;}.pnlLbl{padding:15px 10px 0 10px;}.pnlTrTabOpen .pnlLst{border:none;}.lkpBar{padding:10px 0;}.lkpBar .lkpBtn{float:left;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -80px;margin-left:5px;cursor:pointer;}.pnlFrm{padding-bottom:10px;}.pnlMnu{border:1px solid #e7e7e7;}.pnlMnu .mnuHdr,.rsltHdr{color:#666;font:bold 1.2em Arial,Helvetica,sans-serif;padding:0 0 10px;}a.sbIcon{display:-moz-inline-stack;display:inline-block;width:20px;height:10px;position:static;background:none!important;}a.sbIcon img{display:inline!important;}.sbForm .edit{color:#55B0EB;}#moreSearchRootCont #moreOptsWrp{float:left;margin-right:50px;width:50%;}#moreOptsWrp .headlineViewAs{float:left;margin:5px 5px 5px 0;}#moreOptsWrp .headlineViewAs .viewAsMenu{left:0!important;right:auto;}#moreSearchRootCont #adcntrlPnl{float:left;margin-left:10px;}.botButtonWrap{margin:10px 0;}.botButtonWrap .buttons{float:right;}.columnsCntr:after,.botButtonWrap:after,.snapshotthemes:after,#fdtHldContainer:after,#searchBuilderBoxWrap:after,.cd_div_collapse:after,.ctTab:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.columnsCntr,.botButtonWrap,.snapshotthemes,#fdtHldContainer,#searchBuilderBoxWrap,.cd_div_collapse,.ctTab,.clearFix{zoom:1;}* html .columnsCntr,* html .botButtonWrap,* html .snapshotthemes,* html #fdtHldContainer,* html #searchBuilderBoxWrap,* html .cd_div_collapse,* html .ctTab,* html .clearFix{height:1%;}#searchBuilderBoxWrap{padding-top:6px;clear:both;}#headlineTabs{margin:8px 0 0;padding:5px 0 0;background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;z-index:10;top:1px;}#editws span.shadowL,#editws span.shadowR{display:none!important;}span.shadowL{left:-29px;background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}span.shadowR{right:-29px;background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat 0 0;}* html span.shadowR{right:-15px;}#pageFooter .shadowL{left:-15px;}#pageFooter .shadowR{right:-15px;}.ctTab{list-style:none;padding:0 10px 5px;}.ctTab .tabOff,.ctTab .tabOn{margin-right:10px;}.ctTab .tabOff a{color:#666;font-size:1.1em;text-decoration:none;}.ctTab .tabOff a:hover{color:#333;}.ctTab .tabOff a span{margin-left:2px;}.ctTab .tabOn span{color:#55B0EB;font-size:1.1em;}.fdtContainer{float:left;width:241px;}#fdtWrapper{overflow:auto;position:relative;}.cd_header{cursor:move;position:relative;}.cd_export{padding:3px;position:relative;top:0;z-index:3;color:#666;float:right;}.cd_expand{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_expand{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;}.cd_collapse{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -460px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_collapse{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -460px transparent;}.cd_headerA{color:#999;text-decoration:none;}.cd .cd_header .cd_export a:hover{text-decoration:underline;}.cd_title{position:relative;font-weight:bold;margin:0;padding:5px 3px 5px 45px;cursor:move;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -659px transparent;}#snapsnapshotthemesContent{padding:0 0 5px 20px;}ul.snapshotthemes{margin:0;padding:0;list-style:none;}ul.snapshotthemes li{float:left;display:inline;margin-right:6px;white-space:nowrap;}ul.snapshotthemes li a{float:left;line-height:20px;text-transform:lowercase;}.newsThemes1 a{font-size:.9em;}.newsThemes3 a{font-size:.9em;}.newsThemes5 a{font-size:1em;}.newsThemes7 a{font-size:1.1em;}.newsThemes9 a{font-size:1.2em;}.newsThemes11 a{font-size:1.3em;}.newsThemes13 a{font-size:1.4em;}.newsThemes15 a{font-size:1.4em;}.newsThemes17 a{font-size:1.5em;}.newsThemes19 a{font-size:1.6em;}#fdtBar{float:left;width:10px;height:100%;cursor:pointer;}.fdtHldContainer #fdtBar{background:#efefef url(../img/facelift/handles-sprite.png) no-repeat 0 center;}.fdtHldContainerOff #fdtBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -10px center;}.quoteRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.quoteRow,.clearFix{zoom:1;}* html .quoteRow,* html .clearFix{height:1%;}div.recognition,#appliedFilters{padding:5px 10px;}div.recognition{font-weight:bold;background-color:#ffffe3;}#appliedFilters .filter{font-weight:bold;float:left;}.nofloat{float:none!important;}.DJIIFilterList .beta{float:left;padding-top:2px;padding-right:5px;}#appliedFilters .DJIIFilterList .beta{float:left;padding-top:0!important;padding-right:5px;}#articleFrame #appliedFilters{padding-top:0!important;}#articleFrame #appliedFilters .DJIIFilterList .beta{float:none!important;padding-top:0!important;padding-right:5px;}#newsFilterLst .DJIIFilterList .beta{padding-top:1px!important;}.recognition .suggested a{color:#007ec5;font-weight:bold;}div.quoteRow .quote{display:block;float:left;}div.quoteRow .quoteLinks{display:block;float:left;padding-left:5px;}.quoteLinks a{color:#007ec5;padding:0 5px;border-left:1px solid #666;}.quoteLinks a:hover{text-decoration:underline;}.change-up-new{text-align:right;padding-right:12px;}.change-down-new{text-align:right;padding-right:12px;}#hldContainer{margin:0 0 0 251px;border-left:solid 1px #CCC;}#resultHeader{margin:0 0 0 251px;border-left:solid 1px #CCC;}.splitterContainer{position:relative;overflow:visible;visibility:visible;height:100%;padding:0;background:transparent;border:none;}.clsSplitter{position:absolute;overflow:hidden;visibility:hidden;margin:0;padding:0;border:none;}.clsPane{position:absolute;visibility:visible;margin:0;padding:0;border:none;}.clsPane{overflow:visible;}.clsPane{overflow:auto;}.headlinesView{margin:0!important;overflow-x:hidden;}.headlinesView body.articleView .clsDragBar,body.headlinesView .clsDragBar{visibility:hidden;}.clsDragBar{position:absolute;overflow:hidden;visibility:visible;margin:0;padding:0;background:#CCC;border:none;}#headlineFrame,body.articleView #articleFrame{border-left:solid 3px #EEE;border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame,#headlineFrame{border:none;}#headlineFrame,body.articleView #articleFrame{border:none;}#hldSplitterBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -20px center;}#headlineFrame{height:100%;overflow:hidden;}body.headlinesView #headlineFrame,body.articleView #articleFrame{float:none;width:auto;display:block;}body.headlinesView #headlineFrame{border-left:solid 1px #FFF;}.headlineHeader{padding:5px 5px 8px 0;background : url('../img/facelift/shadowRepeating2.png?42.27.0')  repeat-x 0 0;}#carryOver .headlineHeader{border:none;}.nextItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -540px;padding-right:20px;padding-left:4px;}.previousItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -520px;padding-left:20px;}#dedupSummary{padding:4px 0 0 4px;}#carryOver .headlineHeader span,#carryOver .headlineHeader b,#carryOver .headlineHeader a{display:-moz-inline-stack;display:inline-block;line-height:20px;}#carryOver .headlineHeader #carryOverCount{font-weight:bold;}#carryOverBtn{width:20px;height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -460px;cursor:pointer;}.carryOverOpen #carryOverBtn{background-position:0 -420px;}#carryOver #carryOverBtn span{visibility:hidden;}#carryOverHeadlines{display:none;}.carryOverOpen #carryOverHeadlines{display:block;overflow:auto;border-bottom:1px solid #ccc;}a.carryOverRmv,a.carryOverRmv:visited{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:none;}.saveHeadlines #carryOverHeadlines{display:block!important;}#headlines{overflow:visible;_width:99%;}#headlines{overflow:auto;}.headline a{color:#007EC5;padding-bottom:2px;text-decoration:none;}#headlines a b,.headlines a b,#headlines .caHeadline,#headlines .bgHeadline,#headlines .caHeadline,#headlines .zhtwHeadline,#headlines .zhcnHeadline,#headlines .csHeadline,#headlines .daHeadline,#headlines .nlHeadline,#headlines .enHeadline,#headlines .fiHeadline,#headlines .frHeadline,#headlines .deHeadline,#headlines .huHeadline,#headlines .itHeadline,#headlines .jaHeadline,#headlines .noHeadline,#headlines .plHeadline,#headlines .ptHeadline,#headlines .ruHeadline,#headlines .skHeadline,#headlines .esHeadline,#headlines .svHeadline,#headlines .trHeadline,#headlines .koHeadline,#headlines .idHeadline,#headlines .msHeadline,#headlines .arHeadline{font-weight:bold;}.headline .leadFields{color:#888;font-size:.9em;}.headline .leadFields a{font-weight:normal!important;}.headline .snippet{color:#333;}.enHeadline{font-weight:bold;}.dedupHeadlines{padding:5px 5px 7px;}.mnuBtn,.mnuBtnOpen{color:#666;background-color:#F0F0F0;border:1px solid #D1D1D1;border-right-color:#393939;border-bottom-color:#393939;}.mnuBtn,.mnuBtnOpen{cursor:pointer;}.mnuBtnOpen span{font-size:10px;padding:0 3px;}.mnuBtn span{font-size:10px;padding:0 2px;}body.headlinesView #articleFrame,body.articleView #headlineFrame{float:none;display:none;}#articleFrame{padding:10px;}#articleFrame{border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame{border:none;}#articleFrame,body.framed #articleFrame,body.articleView #articleFrame{padding:0 1px 5px 2px;}#adFrameDiv{padding-top:20px;text-align:center;}.articleHref{line-height:1px;}.articleHeader{margin:0;padding:0 2px 2px 3px;}.articleHeader{margin:0;padding:7px;background-color:#E4E4E4;}.emg_speaker_button_span{position:relative;margin:0 0 0 5px;}.emg_speaker_attribution_cntr{position:relative;color:#999;}div.article{padding:0 10px;}div.article p{margin:1em 0;}.article #hd{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.article #hd a{color:#007ec5;}.article .author{color:#333;margin-bottom:5px;}.article .srcLogo{border:0;}.article .articleParagraph{color:#333;margin-top:5px;}.headerTd{background:#efefef;padding:2px;}div.tabcontent{padding:5px 5px 20px;background:#f4fafe;}div.tabcontent td{padding:0 10px 0 0;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#f4fafe;}#navtab table tr td table{cursor:pointer;}.menulist{display:-moz-inline-stack;display:inline-block;height:26px;padding:2px 0;float:left;}.menulist li{float:left;display:-moz-inline-stack;display:inline-block;width:26px;margin-right:2px;position:relative;}.menulist li .ppsBtn{display:block;text-indent:-9999px;font-size:.1em;width:26px;height:26px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;}.menulist li.ppsview .ppsBtn{background-position:0 0;}.menulist li.ppsemail .ppsBtn{background-position:-26px 0;}.menulist li.ppsprint .ppsBtn{background-position:-52px 0;}.menulist li.ppssave .ppsBtn{background-position:-78px 0;}.menulist li.ppsbriefcase .ppsBtn{background-position:-104px 0;}.menulist li.ppsrtf .ppsBtn{background-position:-156px 0;}.menulist li.ppspdf .ppsBtn{background-position:-130px 0;}.menulist li.ppsxml .ppsBtn{background-position:-182px 0;}.menulist li.ppsnewsletter .ppsBtn{background-position:-208px 0;}.menulist li.ppsquestion .ppsBtn{background-position:-234px 0;}.menulist li.ppclipboard .ppsBtn{background-position:-312px 0;}.menulist li.ppsdeleteselected .ppsBtn{background-position:-364px 0;}.menulist li.ppsview .ppsBtn:hover{background-position:0 -26px;}.menulist li.ppsemail .ppsBtn:hover{background-position:-26px -26px;}.menulist li.ppsprint .ppsBtn:hover{background-position:-52px -26px;}.menulist li.ppssave .ppsBtn:hover{background-position:-78px -26px;}.menulist li.ppsbriefcase .ppsBtn:hover{background-position:-104px -26px;}.menulist li.ppsrtf .ppsBtn:hover{background-position:-156px -26px;}.menulist li.ppspdf .ppsBtn:hover{background-position:-130px -26px;}.menulist li.ppsxml .ppsBtn:hover{background-position:-182px -26px;}.menulist li.ppsnewsletter .ppsBtn:hover{background-position:-208px -26px;}.menulist li.ppsquestion .ppsBtn:hover{background-position:-234px -26px;}.menulist li.ppclipboard .ppsBtn:hover{background-position:-312px -26px;}.menulist li.ppsdeleteselected .ppsBtn:hover{background-position:-364px -26px;}.menulist li.ppsview .ppsBtn.active:hover,.menulist li.ppsview .ppsBtn.active{background-position:0 -52px;}.menulist li.ppsemail .ppsBtn.active:hover,.menulist li.ppsemail .ppsBtn.active{background-position:-26px -52px;}.menulist li.ppsprint .ppsBtn.active:hover,.menulist li.ppsprint .ppsBtn.active{background-position:-52px -52px;}.menulist li.ppssave .ppsBtn.active:hover,.menulist li.ppssave .ppsBtn.active{background-position:-78px -52px;}.menulist li.ppsbriefcase .ppsBtn.active:hover,.menulist li.ppsbriefcase .ppsBtn.active{background-position:-104px -52px;}.menulist li.ppsrtf .ppsBtn.active:hover,.menulist li.ppsrtf .ppsBtn.active{background-position:-156px -52px;}.menulist li.ppspdf .ppsBtn.active:hover,.menulist li.ppspdf .ppsBtn.active{background-position:-130px -52px;}.menulist li.ppsxml .ppsBtn.active:hover,.menulist li.ppsxml .ppsBtn.active{background-position:-182px -52px;}.menulist li.ppsnewsletter .ppsBtn.active:hover,.menulist li.ppsnewsletter .ppsBtn.active{background-position:-208px -52px;}.menulist li.ppsquestion .ppsBtn.active:hover,.menulist li.ppsquestion .ppsBtn.active{background-position:-234px -52px;}.menulist li.ppclipboard .ppsBtn.active:hover,.menulist li.ppclipboard .ppsBtn.active{background-position:-312px -52px;}.menulist li.ppsdeleteselected .ppsBtn.active:hover,.menulist li.ppsdeleteselected .ppsBtn.active{background-position:-364px -52px;}.menulist li ul{display:none;}.mentionedLabelOff{display:none;}.firstRow{color:#FFF;font:bold 1.2em Arial,Helvetica,sans-serif;background-color:#666!important;padding:8px!important;}.even,.even td{background-color:#efefef;}.odd,.odd td{background-color:#FFF;}#framesLink,#noFramesLink{float:right;display:block;text-indent:-9999px;font-size:.1em;height:26px;width:26px;margin:2px 0 0 2px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;text-decoration:none;}#framesLink{background-position:-260px 0;}#noFramesLink{background-position:-286px 0;}#framesLink:hover{background-position:-260px -26px;text-decoration:none;}#noFramesLink:hover{background-position:-286px -26px;text-decoration:none;}#framesLink.active:hover,#framesLink.active{background-position:-260px -52px;}#noFramesLink.active:hover,#noFramesLink.active{background-position:-286px -52px;}.controlsDiv:after,.frames:after,.actions:after,.resultPagination:after,.postProcessing:after,.presentationToggle:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.controlsDiv,.frames,.actions,.resultPagination,.postProcessing,.presentationToggle,.clearFix{zoom:1;}* html .controlsDiv,* html .frames,* html .actions,* html .resultPagination,* html .postProcessing,* html .presentationToggle,* html .clearFix{height:1%;}.headlineOptions{background-color:#e4e4e4;padding:2px 0;background-color:#e4e4e4;z-index:400;height:36px;}.headlineSort{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineDups{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineViewAs{text-align:left;position:relative;display:-moz-inline-stack;display:inline-block;vertical-align:middle;margin:4px 0 0;z-index:405;cursor:pointer;}.headlineViewAs a{display:block;padding:4px;}.headlineOptionsRight .open a,.headlineViewAs a:hover{background-color:#ccc;}.headlineViewAs .viewAs{display:block;padding:0 5px;line-height:20px;}.headlineViewAs .viewAs:hover,.open .viewAs{background-color:#d4d4d4;}.headlineViewAs .viewAsMenu{display:none;width:300px;position:absolute;top:22px;right:0;background-color:#fff;border:1px solid #ccc;z-index:406;}.open .viewAsMenu{display:block;}.headlineViewAs .optionList{height:200px;overflow:auto;background:#fff;z-index:751;}.headlineOptionsRight .open .optionList li a{display:block;padding:2px 5px;background-color:#fff;}* html .headlineOptionsRight .open .optionList li a{display:inline-block;width:100%;}.headlineOptionsRight .open .optionList li a:hover{background-color:#ffffe3;text-decoration:none;}.headlineViewAs .createNewView{margin:0 3px;padding:5px 0;border-top:1px solid #ccc;z-index:751;}.headlineOptionsRight .open .createNewView a{display:inline;color:#666;padding:0;background:none;}.headlineOptionsRight .open .createNewView a:hover{color:#55b0eb;background:none;}.headlineOptions input,.headlineOptions select{line-height:20px;}.buttons:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.buttons,.clearFix{zoom:1;}* html .buttons,* html .clearFix{height:1%;}.buttons{list-style:none;margin:0;padding:0;white-space:nowrap;}.buttons .btn{float:left;position:relative;padding-left:10px;}.buttons .btn .prettyBtn{height:23px;line-height:23px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;padding-left:11px;cursor:pointer;padding-top:0;padding-bottom:0;}.buttons .btn .prettyBtn span{display:block;height:23px;line-height:23px;color:#fff;background-color:transparent;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;}.buttons .btn .prettyBtn{background-position:0 -647px;}.buttons .btn .prettyBtn span{background-position:right -671px;padding:0 15px 0 4px;}.buttons .btn .primaryBtnRight{background-position:0 -257px;}.buttons .btn .primaryBtnRight span{background-position:right -281px;padding:0 22px 0 4px;}.buttons .btn .primaryBtnLeft{background-position:right -744px;padding:0 11px 0 0;}.buttons .btn .primaryBtnLeft span{background-position:0 -768px;padding:0 4px 0 22px;}.buttons .btn .secondaryBtn{background-position:0 -165px;}.buttons .btn .secondaryBtn span{background-position:right -188px;padding:0 15px 0 4px;}.buttons .btn .disabled,.buttons .btn .tertiaryBtn{background-position:0 -353px;}.buttons .btn .disabled{cursor:default;}.buttons .btn .disabled span,.buttons .btn .tertiaryBtn span{color:#999;background-position:right -377px;padding:0 15px 0 4px;}.buttons .btn .disabled span{cursor:default;}.buttons .over .prettyBtn{background-position:0 -695px;}.buttons .over .prettyBtn span{background-position:right -719px;}.buttons .over .primaryBtnRight{background-position:0 -305px;}.buttons .over .primaryBtnRight span{background-position:right -329px;}.buttons .over .primaryBtnLeft{background-position:right -792px;}.buttons .over .primaryBtnLeft span{background-position:0 -816px;}.buttons .over .secondaryBtn{background-position:0 -211px;}.buttons .over .secondaryBtn span{background-position:right -234px;}.buttons .over .tertiaryBtn{background-position:0 -165px;}.buttons .over .tertiaryBtn span{color:#fff;background-position:right -188px;}.buttons .standardBtn{position:absolute;top:0;left:0;right:0;bottom:0;cursor:pointer;}.buttons .standardBtn{opacity:0;filter:alpha(opacity=0);}* html .buttons .btn .prettyBtn{display:inline;}* html .buttons .btn .prettyBtn span{display:inline-block;}ul.floatRight{float:right!important;}.modalHeader:after,.modalFooter:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.modalHeader,.modalFooter,.clearFix{zoom:1;}* html .modalHeader,* html .modalFooter,* html .clearFix{height:1%;}.modal{padding:10px;background-color:#fff;}.modalHeader{padding:10px;background-color:#efefef;}.modalHeader .modalTitle{font-size:1.2em;font-weight:bold;}.modalContent{padding:10px;}.modalFooter{padding:0 10px;}.modalFooter .buttons{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalHeader .supportLink{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalContent .disclaimer{color:#afafaf;margin-bottom:5px;}#emailModal .modalContent .disclaimer a{color:#007ec5;}#emailModal .emailOptions table{width:100%;}#emailModal .emailOptions table td{vertical-align:top;padding:3px;}#emailModal .emailOptions table td .emailUpdate{color:#007ec5;}#emailModal .emailOptions table td.label{text-align:right;}#emailModal .emailOptions table td label{margin:0 5px 0 2px;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.pillOptionsList{cursor:pointer;}.filterText{white-space:nowrap;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}#ml_sc_edit_selected_list .DJIIFilterList li{clear:left;}#sccompanylist .DJIIFilterList li{clear:left;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.DJIIFilterList .pill,.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .pillOption,.pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;}.DJIIFilterList .pill{background-position:0 -402px;}.DJIIFilterList .pill .filterText{background-position:right -419px;}.DJIIFilterList .pillNoMenu{background-position:0 -577px;}.DJIIFilterList .pillNoMenu .filterText{background-position:right -594px;}.DJIIFilterList .filterConnection,.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and{background-position:0 -472px;}.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span{background-position:right -489px;}.pillOptionsList .remove{background-position:0 -542px;}.pillOptionsList .remove span{background-position:right -559px;}.DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -437px;}.DJIIFilterList .pill:hover .filterText,.DJIIFilterList .active .pill .filterText{background-position:right -454px;}.DJIIFilterList .pillNoMenu:hover,.DJIIFilterList .active .pillNoMenu{background-position:0 -612px;}.DJIIFilterList .pillNoMenu:hover .filterText,.DJIIFilterList .active .pillNoMenu .filterText{background-position:right -629px;}.pillOptionsList .or:hover,.pillOptionsList .not:hover,.pillOptionsList .and:hover,.pillOptionsList .remove:hover{background-position:0 -507px;}.pillOptionsList .or:hover span,.pillOptionsList .not:hover span,.pillOptionsList .and:hover span,.pillOptionsList .remove:hover span{color:#fff;background-position:right -524px;}.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and,.pillOptionsList .remove{min-width:100px;height:17px;line-height:17px;padding:0 0 0 6px;}* html .pillOptionsList .or,* html .pillOptionsList .not,* html .pillOptionsList .and,* html .pillOptionsList .remove{width:100px;}.DJIIFilterList .pill,.DJIIFilterList .pillNoMenu,.DJIIFilterList .filterConnection{display:-moz-inline-stack;display:inline-block;float:left;height:17px;line-height:17px;padding:0 0 0 6px;}.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection .connectionText,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:-moz-inline-stack;display:inline-block;height:17px;color:#333;line-height:17px;text-align:center;padding:0 10px 0 4px;}.connectionTextOr,.connectionTextAnd{cursor:default;}#coLst .connectionTextOr,#coLst .connectionTextAnd,#nsLst .connectionTextOr,#nsLst .connectionTextAnd,#inLst .connectionTextOr,#inLst .connectionTextAnd,#reLst .connectionTextOr,#reLst .connectionTextAnd{cursor:pointer!important;}.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:block;}.pillOptionsList .remove span{color:#fff;}.DJIIFilterList .pill .filterText{padding:0 20px 0 4px;}.active .pillOptionsList{display:block;position:absolute;top:17px;right:0;}.appliedFilters .label,.appliedFilters .DJIIFilterList{float:left;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.appliedFilters .label{font-weight:bold;}.noFilterTextIn{background-position:right -593px!important;height:30px!important;}.floatLeft{float:left;}.floatRight{float:right;}.headlineOptionsLeft{float:left;display:-moz-inline-stack;display:inline-block;padding:0 0 0 10px;}.headlineOptionsLeft span{float:left;display:-moz-inline-stack;display:inline-block;padding:6px 0 0;margin:0 5px 0 0;}.headlineOptionsRight{float:right;display:-moz-inline-stack;display:inline-block;padding:0 10px 0 0;z-index:403;text-align:right;}.headlineOptionsRight span{position:relative;display:-moz-inline-stack;display:inline-block;z-index:749;margin:4px 0 0;vertical-align:middle;}.headlineOptionsRight span span,.headlineOptionsRight span span span{margin:0;}#mentionedLabel1{z-index:401;}#mentionedLabel1 div{z-index:402;}#mentionedLabel1 .postprocessinglinks{margin:2px 5px 0 5px;padding:0;}.clear{clear:both;}.marginLeft_0px{margin-left:0!important;}.paddingLeft_10px{padding-left:10px!important;}.headlines tr.over{background:#FFFFE3;}#directLinkBox .overlayfooter ul{float:right;}#directLinkBox td{padding:3px;}.overlaycontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:600px;margin:20px;position:relative;}.overlayrenamecontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:350px;height:120px;margin:20px;position:relative;}.overlayclose{background : url('../img/close.png?42.27.0')  no-repeat;_background : url('../img/close2.gif?42.27.0')  no-repeat!important;cursor:pointer;position:absolute;width:25px;height:25px;right:-15px;top:-15px;}* html .overlayclose{background : url('../img/close.gif?42.27.0')  no-repeat;}.overlayheader{font-family:Arial,Helvetica,sans-serif;font-size:12px;font-weight:bold;margin:10px;background:#4b4b4b;padding:7px;color:#fff;}.overlaybody{margin:10px;}.overlaytable{border-collapse:separate;border-spacing:5px;}.overlaytable td{vertical-align:middle;}.overlaytitle{width:120px;white-space:nowrap;}.overlayselect{border:solid 1px #ccc;width:300px;}.overlaycreatelist{border:solid 1px #ccc;width:296px;}.overlaylink{color:#309;cursor:pointer;padding-left:5px;padding-right:5px;}.overlaylinkdisable{color:#ccc;cursor:none;}.overlayline{margin-top:5px;margin-bottom:15px;border:solid 1px #ccc;}.overlaytext{border:solid 1px #ccc;width:300px;}.overlaysourcelist{height:160px;overflow:auto;}.overlayitem{border:solid 1px #FBE0A8;background:#FBE0A8;padding:2px 5px 2px 5px;margin-bottom:2px;}.overlayfooter{margin:10px;}.overlaytextbold{font-weight:bold;}.ceprogress{display:none;background-color:#fff;border:1px outset #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;z-index:10006;width:140px;text-align:center;padding:5px;}.ceerror{color:#f00;}.overlaypillscontextmenu{position:absolute;display:none;z-index:10002;}#directLinkBox .overlayfooter{position:relative;}#directLinkBox{height:auto!important;}.resultsBar{padding-left:4px;}#mbBody .resultsBar{left:49px;position:absolute;}#editws #mbBody .resultsBar{left:inherit!important;position:inherit!important;top:inherit!important;}#editws #mbBody #selectAll{float:left;}#editws #mbBody #clearAll{float:left;}.search_autosuggest_over{background-color:#55B0EB!important;color:white;cursor:pointer;}.printheadline{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.nomargin{margin:0!important;}.nopadding{padding:0!important;}.ea #contentWrapper{width:100%!important;}.ea #contentWrapper input,.ea #contentWrapper textarea{width:90%!important;}#trackHeads33 .alertsHeader{float:left;}#trackHeads33 table td{vertical-align:middle;}#trackHeads33 .alertsHeader #folderDDLabel{margin-right:5px;color:#333;font-size:1.2em;line-height:26px;}#trackHeads33 .alertsHeader .alertsList{margin-right:5px;}.searchOptions{float:right;display:inline-block;height:23px;}.searchOptions .editAlert,.searchOptions .changeAccess,.searchOptions .alertOptions{display:inline-block;line-height:26px;padding:0 3px;color:#333;}.searchOptions .alertOptions{color:#55B0EB;}.searchOptions .alertOptions a{display:inline-block;background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -417px;padding:0 20px 0 0;}.alertOptions{position:relative;}.alertOptionsMenu{display:none;}.open .alertOptionsMenu{display:block;height:175px;width:200px;position:absolute;top:23px;right:0;background-color:#fff;border:1px solid #ccc;}.xmlLinkWithIcon{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -3px;}.xmlLinkWithIcon:hover{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -29px;}.alertList{display:inline-block;height:20px;position:relative;margin:0 5px 0 0;z-index:100;}.alertListLink{display:inline-block;width:212px;color:#333;line-height:20px;background:#eee url(../img/facelift/facelift-icon-sprite.gif) no-repeat right -498px;padding:0 5px;}.open .alertListLink,.alertListLink:hover{background-color:#d7d7d7;}.alertListMenu{display:none;position:absolute;width:200px;background-color:#fff;border:1px solid #ccc;}.open .alertListMenu{display:block;left:0;top:20px;}.alertListMenu ul li{padding:0;}.alertListMenu ul li .alertTypeSectionHead{display:block;line-height:12px;padding:3px 5px;background-color:#f3f3f3;}.alertListMenu ul li a{display:block;color:#333;line-height:12px;padding:2px 5px 2px 25px;vertical-align:top;}.alertListMenu ul li a:hover{background-color:#dbeefc;}* html .alertListMenu ul li .alertTypeSectionHead,* html .alertListMenu ul li a{height:12px;}.hr{height:100px;}#emtRow td{height:1px;}.ceprogress,.confirmDialog,.messageDialog{background-color:#fff;border:1px solid #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;font-weight:bold;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;text-align:center;padding:10px 30px 10px 30px;}.confirmDialog,.messageDialog{border:5px solid #555;padding:20px 30px 15px 30px;}.ceerror{color:#f00;}#messageDialogOk td{padding-top:15px;text-align:center;}#messageDialogOk td ul{width:50px;float:none!important;}#messageDialogOk .btn{margin-left:0;}#confirmDialogButtons td{padding-top:15px;text-align:center;}#confirmDialogButtons td ul{width:120px;float:none!important;}#confirmDialogButtons #confirmDialogYes{margin-left:0;}.modalPage{margin:0;}.modalPage #contentWrapper{padding:0;width:800px;}#bottomSaveCanc{padding-right:48px;}.foldersDeliveryOptions table{padding:10px;width:100%;}.foldersDeliveryOptions td{padding:5px;}.foldersDeliveryOptions .delMnu{height:552px;width:100%;}.foldersDeliveryOptions .botButtonWrap .buttons{width:100%;}.foldersDeliveryOptions #tdFirst{width:33%;}.foldersDeliveryOptions #tdSecond{width:20%;}.foldersDeliveryOptions #tdThird{width:39%;}.foldersDeliveryOptions .itemText{margin-top:0;}#topBox{background-color:#fff;}#bottomBox{background-color:#fff;}.foldersDeliveryOptions .buttons li{padding:10px;}.foldersDeliveryOptions .buttons .btn{float:none;}.foldersDeliveryOptions .modalCancel{bottom:0;cursor:pointer;left:0;opacity:0;position:absolute;right:0;top:0;}#trOne{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#trTwo{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#tdOne{border-left:1px solid #999;padding-left:0;padding-bottom:0;padding-right:0;border-bottom:1px solid #999;border-right:1px solid #999;}#tdZeroRightP{padding-right:0;border-right:1px solid #999;border-top:1px solid #999;}#tdZeroRightPEX{border-top:1px solid #999;}*#tdZeroRightPEX{*border-left:1pxsolid#999;}#tdZeroRightPNoT{padding-right:10px;border-right:1px solid #999;border-bottom:1px solid #999;}#tdZeroRightPNos{border-bottom:1px solid #999;}*#tdZeroRightPNos{*border-left:1pxsolid#999;}.menuSelected{background-color:#dbeefb!important;}.menuItemC{color:#000;margin-top:2px!important;float:left;text-decoration:none;margin-left:4px;}.foldersDeliveryOptions .mnuItm{padding-top:2px;padding-bottom:2px;margin-top:2px;float:left;text-decoration:none;margin-left:4px;background-color:transparent;border-color:#999;border-width:1px;z-index:800;}.delMnu li,.delMSel li,.delASel li{z-index:900;}.delMnu li a,.delMSel li a,.delASel li a{z-index:800;}#afternoonListC select{border:none;}#morningListC select{border:none;}.foldersDeliveryOptions .delMnu ul{margin:0 0 2px;z-index:1;}.folderClosed{cursor:pointer;z-index:800;height:20px;}.delMSel a:focus,.delMSel a:hover,.delASel a:focus,.delASel a:hover,.delMnu a:focus,.delMnu a:hover{color:#000;}.delMSel{overflow:auto;height:200px;}.delASel{overflow:auto;height:200px;}#morningListC{margin-top:-3px;}#afternoonListC{margin-top:-3px;}.dragSelected{background-color:#dbeefb;}.deliveryOptions{margin-bottom:20px;}.botButtonWrap{margin-left:0;}.foldersDeliveryOptions .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.foldersDeliveryOptions .orderUp{cursor:pointer;background : url('../img/up.png?42.27.0')  no-repeat;height:24px;width:24px;margin-bottom:5px;}.foldersDeliveryOptions .orderDown{cursor:pointer;background : url('../img/down.png?42.27.0')  no-repeat;height:24px;width:24px;}*.foldersDeliveryOptions .buttons .btn .prettyBtn span{*width:115px;*margin-right:0;}#dcSaveAuxCntr .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.modalPage .modalFooter .buttons{padding-left:0;float:left;}.modalPage #dcSaveEditCntrL1{float:left;width:196px;}.modalPage #dcSaveEditCntrL2{float:left;}.modalPage #dcSaveCreateCntrL1{float:left;margin-top:20px;width:196px;clear:both;}.modalPage #dcSaveCreateCntrL2{float:left;margin-left:-3px;margin-top:20px;width:250px;}.modalPage #dcSaveCreateCntrL3{float:left;margin-left:-3px;width:250px;margin-top:20px;}.modalPageTopContainer{width:700px;}.modalPage #dcSaveBodyCntr{float:left;position:relative;padding-bottom:20px;width:810px;}.modalPage #RnmLnk{margin-left:5px;margin-right:5px;}.modalPage #dcSaveAuxCntr{float:left;margin-bottom:20px;position:relative;width:100%;}.modalPage #dcSaveAuxCntr td{width:300px;padding-left:20px;padding-right:20px;padding-top:2px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItm{padding-top:3px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItmSelected{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}.SSeleted,.CSeleted{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}#dcSaveAuxCntr .buttons li{margin-top:30px;float:none;}#dcSaveAuxCntr .botButtonWrap{width:124px;}#dcSaveAuxCntr .botButtonWrap .buttons{width:115px;float:none;}.mnuItmAdded{border:1px solid #BABCD1;background-color:#dbeefb!important;}#leftSControl,#rightSControl{padding-top:2px;padding-bottom:2px;margin-top:2px;background-color:transparent;height:400px;border:1px solid #BABCD1;width:265px;}#leftSControl .mnuItm,#rightSControl .mnuItm{background-color:transparent;margin-left:4px;}#leftSControl .folderClosed,#rightSControl .folderClosed{padding:2px;}#leftSControl .menuItemC,#rightSControl .menuItemC{margin-top:0!important;}#ContainerEAT p.button-row{text-align:left;}#ContainerEAT td{padding:3px;}#ContainerEAT .buttons .minorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#ContainerEAT .botButtonWrap{float:none;clear:both;}#ContainerEAT .botButtonWrap .buttons{float:none;clear:both;}#ContainerEAT{clear:both;margin-bottom:-10px;}#sendDivE{margin-left:-10px;}#ContainerEAT .buttons .majorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#emailSentC{width:520px;}#emailSentC ul{float:right;}#messageTop{margin-top:20px;margin-bottom:40px;}.lTD{text-align:right!important;width:170px;}#idNoResults{margin-bottom:40px;margin-top:20px;}#widgetFolderContainer div.tip{margin:10px 0 10px 5px;}.margin_10px{margin:10px;}.marginTop_10px{margin-top:10px;}.marginBottom_10px{margin-bottom:10px;}.marginRight_10px{margin-right:10px;}.marginTop_5px{margin-top:5px;}.marginBottom_5px{margin-bottom:5px;}.padding_10px{padding:10px;}.paddingBottom_15px{padding-bottom:15px;}.paddingBottom_10px{padding-bottom:10px;}.paddingBottom_0px{padding-bottom:0!important;}.paddingTop_10px{padding-top:10px;}.paddingRight_10px{padding-right:10px;}.paddingLeft_10px{padding-left:10px;}.paddingLeft_0px{padding-left:0!important;}.paddingLeft_5px{padding-left:5px;}.paddingRight_5px{padding-right:5px;}.txtBold{font-weight:bold;}.txtLight{color:#aaa;}.txtRight{text-align:right;}#articleViewAs ul li a.selected{background-color:#FFFFE3;}.overlaybody .close{display:none;}.articleParagraph b{font-weight:bold!important;}.odeArticle Table{padding:5px;}.odeArticle td{padding:5px;}.odeArticle p{margin-bottom:10px;}#SaveButCreate{margin-top:5px;margin-bottom:-10px;}#articleViewAs .pnlTab{width:100px;}#articleViewAs .pnlTabOpen{width:115px;}.cssQuotePage #contentLeft{float:left;}.cssQuotePage #inpfid{float:left;width:170px;}body.cssQuotePage #contentLeft,body.cssQuotePage #contentLeft div.module{width:320px;}.cssQuotePage #contentRight{margin-left:325px;height:100%;}.cssQuotePage b{font-size:100%;font-weight:bold;position:relative;top:-1px;}.cssQuotePage td,.cssQuotePage th{font-size:100%;}.cssQuotePage .title td{padding:5px;}#ml_main .buttons .btn .prettyBtn span{text-align:center;}.cssWidth2P{width:2%;background:none repeat scroll 0 0 #E8E8E8;}.cssWidth38P{width:38%;}.cssWidth60P{width:60%;}.css_ml_cellTD1{width:40%;}.css_ml_cellTD2{width:30%;}.css_ml_cellTD3{width:30%;}.ml_css_section{padding-bottom:10px;}#ml_sc_table1,#ml_sc_table2{width:100%;}#ml_co_table1,#ml_co_table2{width:100%;}#ml_qo_table1,#ml_qo_table2{width:100%;}#ml_sc_table2,#ml_co_table2,#ml_qo_table2{background-color:#FFF;border:1px solid #EFEFEF;}#ml_sc_table2 td,#ml_co_table2 td,#ml_qo_table2 td{border-bottom:1px solid #EFEFEF;font-size:10px;font-weight:normal;height:30px;padding:0;text-align:left;vertical-align:middle;}.css_ml_titlerow{padding:5px;background:#e8e8e8;}.css_ml_title{cursor:pointer;font-weight:bold;}.css_ml_header{padding:10px;background:#f5f5f5;font-weight:bold;}.css_ml_toggle{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;height:18px;width:15px;cursor:pointer;}.css_ml_toggle.close{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}.css_ml_message{text-align:center;}.css_ml_cell{padding:8px;border-bottom:solid 1px #f5f5f5;border-left:solid 1px #f5f5f5;}.css_ml_row_hover{background:#CDE7FC;}.css_ml_cell_last{border-right:solid 1px #f5f5f5;}.css_ml_link{padding-left:10px;color:#55b0eb;cursor:pointer;}.css_ml_link:hover{padding-left:10px;color:#55b0eb;}.css_ml_separator{padding-left:10px;color:#ccc;}.overlaylist{height:90px;overflow:auto;border:solid 1px silver;overflow:auto;margin-bottom:5px;padding:5px;}.overlaybar{margin-bottom:5px;}.overlaysearchbutton{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;width:20px;height:20px;margin-left:5px;cursor:pointer;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}#ml_co_searchnameonly{margin-right:10px;}.lf{cursor:pointer;}.spacer_10px{height:10px;overflow:hidden;}.dj_tophat-firstview{background : url('../img/tile_background.png?42.27.0')  repeat-x scroll 0 0 transparent;font-family:arial,sans-serif;position:relative;}.dj_tophat-firstview .dj_header-panel .wrap{margin:0 auto;padding-left:40px;padding-right:40px;}.dj_tophat-firstview .dj_information .wrap{background:none;height:194px;margin:0 auto;width:1025px;}.dj_tophat-firstview .dj_header-panel{background:none repeat scroll 0 0 #424242;border-bottom:1px solid #535353;height:30px;}.dj_tophat-firstview .dj_header-panel h1{color:white;float:left;font-size:12px;margin:8px 0 0;padding:0;cursor:pointer;font-weight:bold;}.dj_tophat-firstview .dj_header-panel h2.disable{background : url('../img/close_button.png?42.27.0')  no-repeat scroll right center transparent;color:#999;cursor:pointer;float:right;font-size:12px;margin-top:8px;padding:0 30px 0 0;}.dj_tophat-firstview .dj_information{background : url('../img/grid_background.png?42.27.0')  no-repeat scroll center center transparent;display:block;height:196px;}.dj_tophat-firstview .dj_information img{float:left;margin-top:10px;}.dj_tophat-firstview .dj_information h3.dj_beta{background : url('../img/beta_tag.png?42.27.0')  no-repeat scroll right top transparent;color:white;display:inline;font-size:26px;font-weight:normal;margin:0;padding:0 40px 0 0;text-shadow:0 0 5px #000;}.dj_tophat-firstview .dj_information .dj_text{float:right;margin-top:25px;width:630px;}.dj_tophat-firstview .dj_information p{color:white;font-size:16px;line-height:1.5;margin:10px 0 0;padding:0;width:400px;}.dj_tophat-firstview .dj_information ul.dj_next{float:right;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li{display:inline;list-style-type:none;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li a{color:white;font-size:12px;font-weight:bold;text-decoration:none;}.dj_tophat-firstview .dj_information ul.dj_next li.get_started a{-moz-border-radius:10px 10px 10px 10px;-webkit-border-radius:10px 10px 10px 10px;border-radius:10px 10px 10px 10px;background:none repeat scroll 0 0 #93BE4E;padding:5px 10px;}.dj_tophat-firstview .dj_information ul.dj_next li.later a{color:#CCC;}.cellPadding_3px td{padding:3px;}.cellPadding_5px td{padding:5px;}.cellValignTop td{vertical-align:top;}.cssArticleO .DJIIFilterList .pill .filterText{background-position:right -594px;}.cssArticleO .DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -402px;}.displayBlock{display:block;}.groupAdmin table.searchoptions td.Off{border:1px solid #fff!important;padding:1px!important;}#ml_sc_edit1overlay{height:470px;width:600px;}.admnSSID #ssidTable{background-color:#b1babb;}.pnlMnu li ul{margin:0 0 0 20px;padding:0;}.pnlMnu li{margin:0;padding:2px 0;}.pnlMnu ul{list-style-type:none;margin:0;padding:0 0 5px;}#dateAndDupRow .sbSubmit .floatRight{padding-right:10px;}#npModal .npMnu,#npModal .npMnu2{padding:0;}#npModal .npMnu ul{margin:0;}#npModal .mnuItm{margin-left:5px;}#npModal .mnuItm{background-color:transparent;}#npModal .mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.addRemBtn .buttons .btn{float:none;margin-top:10px;}#npModal #issmd{margin-left:25px;}#npModal #ifmd{margin-left:25px;}#npModal #isosmd{margin-left:25px;}#npModal .svCBtn{float:right;width:200px;}#npModal .npMnu li{padding-top:2px;padding-bottom:2px;}#npModal .npMnu li ul{margin-left:17px;}#npModal .folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -134px -94px;margin-left:5px;}.sharedClosed{height:20px;}#npModal .sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -104px -110px;margin-left:5px;}#npModal .buttons .btn .primaryBtnLeft span{text-align:center;}.norecords div{padding-left:25px;}#siteAlertMain .close a{background: transparent url('../img/close_icon.gif?42.27.0')  no-repeat 0 0;height:17px;position:absolute;right:18px;top:5px;width:17px;}.overlaycontainer #d1cnt span{display:inline-block;position:static;}.mnuBtnOff span{display:inline-block;position:relative!important;top:-5px!important;}#ml_sc_list .mnuBtnOff span{display:inline-block!important;position:static!important;}#ml_sc_list .mnuBtnOff{display:inline-block!important;position:static!important;}.overlaylist li ul li{margin-left:10px;}#ml_sc_editoverlay .searchBuilderFilters{position:relative;}#ml_sc_editoverlay .overlaylist{position:relative;}.btnWidth{width:130px!important;float:left;margin-bottom:10px;}.cqscTopDiv{margin:5px;padding-top:20px;}.cqscCodingS{float:left;width:110px;}.cqscSearchText{float:left;margin-left:10px;}.cqscBtnSear{float:left;width:100px;}.cqscSelectFromList{float:left;margin-top:10px;width:100px;}.cqscCompanyListControl{float:left;margin-right:10px;margin-top:10px;width:180px;}.cqscSelectList{float:left;width:110px;margin-top:10px;}.bdbulkmn{width:auto!important;}.tableCellPadding_5px td{padding:5px;}.tableCellPadding_3px td{padding:3px;}.tableCellPadding_5px th{padding:10px;}.actionNodes span{display:inline-block;}.quoteOuterD{height:340px;}.ssCOut{height:30px;}.ssC1but{width:100px;height:30px;}.ssC2but{height:30px;}#scl{width:180px;}#qicl{width:180px;}.mdsChartTitle{padding-top:10px;}.entrie table tbody tr th{padding-top:10px;padding-bottom:10px;font-weight:bold;}.entrie table tbody tr td{padding-top:5px;padding-bottom:5px;}#edittable td{padding:5px;align:center;}#edittable th{padding:5px;}#addtable td{padding-top:5px;padding-bottom:5px;}#addtable th{padding:5px;}.margin5PX{padding:5px;}.greyTbl th{padding:10px;}.width200PX{width:200px;}.width150PX{width:150px;}.width100PX{width:100px;}#ttDiv .btnTTC{margin-top:10px;}.cssPaddingRight10px{padding-right:10px;}.tt_mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.pnlLst{vertical-align:top;height:22px;}.height80PX{height:115px!important;}.cssArticleO{height:182px;}#gl-navBottom{min-width:960px!important;}#gl-navBottomMiddle{min-width:960px!important;}* html .cssIE6MinWidth{*padding-left:1100px!important;*height:1px!important;}* html .cssIE6MinWidthAdj{*margin-left:-1100px!important;*position:relative!important;*height:1px!important;}* html .cssIE6MinWidthAdjLay{*height:1px!important;}.sbinfoIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -304px transparent;display:inline-block;width:20px;}.addFIICodeIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -144px transparent;display:inline-block;width:20px;}.searchoptions td a{color:#906;padding:2px 2px 2px 5px;}.searchoptions .searchContainer td{color:#000;font-weight:bold;border:0 solid white;}.searchoptions td{padding:3px;background-color:#EAEBF5;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;height:13px;border:1px solid white;}.searchoptions tr{color:#000;}.searchoptions #Header td{padding:3px;background-color:#999!important;color:#fff;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;font-weight:bold;height:13px;border:1px solid white;}.searchoptions #Header tr{color:#000;}#NoBody td{padding:2px;background-color:white;color:white;}div.content,div.exContent,div.contentWithTabs,div.scrContent{zoom:1;}.searchContainer{background : url('../img/bar_lt_news.gif?42.27.0')  no-repeat scroll;color:#000;font-family:Arial,Helvetica,sans-serif;text-decoration:none;margin-bottom:10px;padding-right:10px;position:relative;vertical-align:middle;zoom:1;}.searchContainer td{padding:3px;color:#000;border:none;}#npModal .subTitle{color:#FFF;}.overlaylist{position:relative;}.overlaylist #d1cnt{overflow:hidden;}.arHeadline{direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.sssuggest{padding-top:5px;margin:10px 0 0 37px;font:arial 12px;color:#666;border-top:#e6e7e8 1px solid;}#ssp{display:none;}#sspDiv{_width:560px;}.sspDesc{padding:0 0 10px 0;width:470px;margin:0 40px 0 40px;}.sspDesc1{text-align:center;padding:15px 0 20px 0;font-size:18px;font-weight:bold;}.sspDesc2{font-size:12px;}.sspDesc2 ul{list-style-type:none;padding:0;margin:0;}.sspDesc2 li{padding-bottom:10px;}.sspInputWrapper{border:1px solid #8c92b1;padding:10px 10px 10px 10px;margin-left:40px;margin-right:40px;white-space:nowrap;background-color:#e2e6f3;}.ssatx{font-size:16px;border:1px solid #d6d6d6;}.sspNoThanksDiv{padding:15px 0 15px 0;text-align:right;margin-left:20px;margin-right:20px;}#sspDiv div.floatRight{display:none;}#sspDiv,#sspDiv .popupHdr{background-color:#E1E1E1;}#sspBody{background-color:#EFEFEF;}.dj_emg_autosuggest_odd{background-color:#EEEDED!important;}.dj_emg_autosuggest_even{background-color:#FFF!important;}.dj_emg_autosuggest_over{background-color:#d8e2e5!important;color:Black!important;}.dj_emg_autosuggest_results{background-color:#FFF;z-index:100000!important;width:600px!important;}.scResultPopup{width:600px!important;}a.ac_info{background-image : url('../img/sbInfo.gif?42.27.0') !important;}a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:block!important;}.clsScrFrm a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:none!important;}#bkScrn{position:absolute;left:0;top:0;background:#A5A5A5;display:none;z-index:998;}a.ac_not{background: transparent url('../img/exclude.png?42.27.0')  no-repeat scroll center center!important;}* html #gl-navTop #gl-navTopLeft h1{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat 0 -209px;}* html #gl-navTopRightUl li#mbrightddtbm1,* html #gl-navTopRightUl li#mbrightddtbm0{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -4px;}* html #gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat left -64px;}* html #gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{background-image : url('../img/facelift/facelift-icon-sprite-darkgrayMatte.gif?42.27.0') ;}* html #gl-navBottom{background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;}* html #gl-navBottomMiddle{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -132px;}* html #gl-navBottomMiddle ul#menulist{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -99px;}* html #gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 0;}* html #gl-navBottomMiddle ul li.selected a{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;}* html #gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -33px;}* html .footerBrand{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -40px;}* html .ftright{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -80px;}* html .fcsclose,* html .fcsopen{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .pnlTab .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}* html .pnlTabOpen .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;}* html .lkpBar .lkpBtn{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;}* html .cd_title{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -659px transparent;}* html .sbTable .shadowTopLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px 0;}* html .sbTable .shadowTopRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -12px;}* html .sbTable .shadowLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y 0 0;}* html .sbTable .shadowRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y -12px 0;}* html .sbTable .shadowBotLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -36px;}* html .sbTable .shadowBotRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -24px;}* html .menulist li a{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat 0 0;}* html .tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -40px transparent;}* html .tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -20px transparent;}* html .firstDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -322px transparent;}* html .secondDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -342px transparent;}* html .scheduledDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -382px transparent;}* html .continuousDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -363px transparent;}* html .onlineDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -683px transparent;}* html .xmlLink.xmlLinkWithIcon{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -400px transparent;}* html .DJIIFilterList .pill,* html .DJIIFilterList .pill .filterText,* html .DJIIFilterList .pillNoMenu,* html .DJIIFilterList .pillNoMenu .filterText,* html .DJIIFilterList .filterConnection,* html .DJIIFilterList .filterConnection .connectionText,* html .pillOptionsList .pillOption,* html .pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html #fdtHldContainer{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;}* html .cd_expand{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .nextItem,* html .previousItem{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}#qooverlay .buttons{margin-top:16px;}#qooverlay .overlayline{margin-bottom:5px;}#qocompanylist{height:70px;overflow:auto;position:relative;}.overlaycompanylistProgress{border:1px solid #CCC;}.NewsPages #contentWrapper #contentLeft{float:left;width:36%;}.NewsPages #contentWrapper #contentRight{float:left;margin-left:15px;width:59%;}.cssRemoveOverFlowIPAD{height:auto!important;overflow:hidden!important;}.NewsLetter{margin:0;}.WorkSpace{margin:0;}.NewsLetter #contentWrapper{padding:0;}.cssGroupFolder{background : url('../img/blueDott.JPG?42.27.0')  no-repeat scroll 0 0 transparent!important;height:10px;padding-left:15px;}.cssNoDisplay{display:none;}.snippet b{font-weight:bold;}.pagePadding{margin-left:10px;margin-right:10px;}#NLContainer td{padding:0;}#mbBody #selectAll,#mbBody #selectAll a{height:17px;width:15px;}#mbBody #selectAll,#mbBody #selectAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -130px transparent;}#mbBody #clearAll,#mbBody #clearAll a{height:17px;width:15px;}#mbBody #clearAll,#mbBody #clearAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -150px transparent;}#mbBody .headlineHeader{padding-bottom:5px;background-color:#ccc;padding-left:5px;padding-right:5px;padding-top:5px;margin-bottom:10px;height:1%;}.showButllet{background : url('../img/arrowb.gif?42.27.0')  no-repeat 2px 4px transparent!important;zoom:1;}.overlaylist .lookupdyn{display:none;}a.sbIcon img{display:inline-block!important;vertical-align:baseline!important;}.overlaycontainer .mnuItmInc{color:#55B0EB!important;text-decoration:none!important;}.overlaycontainer .mnuItmExc{color:#55B0EB!important;text-decoration:line-through!important;}.overlaycontainer .addFiiCode{display:none!important;}.overlaycontainer a.sbIcon{width:0!important;padding-left:5px;}.overlaycontainer .availLbl{margin-left:25px;_margin-left:15px;}.overlaycontainer .availLbl img{_margin-bottom:5px;}#mdsLookupControl a:visited,#mdsLookupControl a:link,#mdsLookupControl a:hover{text-decoration:underline!important;}#chrtHCorpBond .WidgetContainer{background-color:#e5e5e5!important;}.WidgetBodyControls{position:relative;}.overlaylist .availSrchLbl{margin-left:25px!important;}.overlaylist .sbImg{margin-left:10px!important;}.NewsFiltersFilter{-moz-border-radius:5px;display:block;float:left;line-height:20px;margin-right:5px;padding-left:5px;margin-bottom:2px;background-position:0 -402px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;}.NewsFiltersFilter .label{float:left;line-height:20px;white-space:nowrap;}.NewsFiltersFilter .icon-close{background-image : url('../img/icon_filter_close.png?42.27.0') ;background-position:center top;cursor:pointer;display:block;float:left;height:20px;width:20px;}.NewsFiltersFilter .icon-close:hover{background-position:center bottom;}.filterTextRemove{background-position:right -857px!important;}.DJIIFilterList .pill:hover .filterTextRemove,.DJIIFilterList .active .pill .filterTextRemove{background-position:right -892px!important;}.alphaHdr{background-color:#F0F0F0!important;cursor:default;}.alphaHdr a{padding-right:3px;}#dialogWindow .header .close{background-image:none!important;}body.framed #headlines{overflow:auto;overflow-x:hidden;}body.framed #headlineFrame{float:left;width:50%;}#returnToHeadlines{display:none;}body.articleView #returnToHeadlines{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}#returnToHeadlines a{padding:4px;}body.articleView #ppsview,body.articleView #viewSelected,body.articleView #headlineSort,body.articleView #dedupDropdown{display:none;}#headlineSort,#viewSelected{display:inline;}#pageFooter{clear:both;}.headline a:active{color:#007ec5;text-decoration:none;}.headline a:hover{color:#007ec5;text-decoration:underline;}.headline a:visited,.headline a:visited{color:#007ec5;text-decoration:none;}.headline a.moreLikeThis,.headline a.moreLikeThis:visited{color:blue;font-weight:normal;text-decoration:none;}#headlines a b,.headlines a b{color:#000;}.headline a.moreLikeThis:hover{color:blue;font-weight:normal;text-decoration:underline;}.searchPreview td{border-bottom:solid 1px #CCC;padding:3px 0 3px 8px;}.searchPreview .label{color:#666;}body.framed #bottomHeadlineNav,body.articleView #bottomHeadlineNav{display:none;}body.headlinesView #bottomHeadlineNav{display:block;}div.indexingHeader span.left,div.indexingHeader span.right{float:left;position:relative;}div.indexingHeader span.right{float:right;}#articleFrame a.moreLikeThis{color:#666;text-decoration:none;}#articleFrame a.moreLikeThis:hover{color:#000;text-decoration:underline;}.indexingHeader{background-color:#FC3;font-weight:bold;padding:7px;}.indexingPanel{background-color:#FF9;}.articleComment{background-color:#FFC;padding:3px;}a.carryOverRmv:hover{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:underline;}.folderList{width:175px;}.viewType{padding-top:5px;}body.articleView .viewType{display:none;}span.hot{border:solid 1px #CCC;}span.hot span{border-left:solid 10px #F00;color:#F00;}span.new{border:solid 1px #CCC;}span.new span{border-left:solid 10px #F69;color:#F69;}span.mustRead{border:solid 1px #CCC;}span.mustRead span{border-left:solid 10px #9C0;color:#9C0;}span.comment{border:solid 1px #CCC;}span.comment span{border-left:solid 10px #FC0;color:#FC0;}#newsstandTitle{float:left;padding-bottom:10px;}#returnLink{float:right;padding-bottom:10px;}span.hldScore{font-weight:bold;}.linkhide{float:right;margin-right:10px;cursor:pointer;padding-right:1px;}div.dymFreeText{padding-bottom:0;margin-bottom:0;margin-right:10px;display:inline-block;height:20px;vertical-align:middle;width:100%;}* html div.dymFreeText{height:20px;padding-top:4px;padding-bottom:0;margin-bottom:0;margin-right:10px;}div.recognitiondym,#appliedFilters{padding-top:5px!important;padding-bottom:0!important;margin-top:2px;}div.recognitiondym{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x scroll 0 0 transparent;margin:5px 0;padding-left:5px;border:solid 1px #DBDBE7;display:block;}.freeText{padding-left:5px;}.dymTitle{display:block;}.dymInput{padding:1px;margin:0;}.dymCollapsiblePanel{padding-top:3px;}.dymCollapsiblePanelCollapsed{padding-top:3px;display:none;}.dedupHd{display:none;}#dedupHoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;width:285px;z-index:10000;}#dedupHiddenHH{display:none;}dedupHoverHintShim{position:absolute;}.dedupCount{color:#309;font-style:normal;}#analyzeChecked{background-color:#F63;background-repeat:repeat-x;color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;height:16px;padding-bottom:1px;padding-left:4px;padding-right:4px;padding-top:1px;text-align:center;}#analyzeChecked A:active,#analyzeChecked A:visited,#analyzeChecked A:link,#analyzeChecked A:hover{color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-align:center;text-decoration:none;}.hintImg{border:0;padding:0;vertical-align:middle;}#feedHH{display:none;}.hoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;z-index:10000;}body.articleView TABLE#contentColumns{table-layout:fixed;}.viewAs{display:none;}body.articleView #articleViewAs{display:inline-block;}body.articleView #returnToPreviousPage{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}body.articleView #returnToPreviousPage a{display:block;padding:4px;}.hlAuthorLink{font-weight:normal;}.headline .leadFields a{color:#63c;font:1em Verdana,Geneva,sans-serif;font-weight:normal;text-decoration:none;}.headline .leadFields a:hover{color:#63C;font-weight:normal;text-decoration:underline;}#atlnk{outline:none;}.headerTd{background:#ffd659;padding:2px;}div.tabcontent{background:#FFFFE3;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#FFFFE3;}#navtab table tr td table{cursor:pointer;}#ssButtonContainer{background : url('../img/left_button.gif?42.27.0')  no-repeat left center;height:32px;padding-left:5px;cursor:pointer;display:inline-block;_width:1%;}#ssButtonSubContainer{background : url('../img/right_button.gif?42.27.0')  no-repeat right center;height:32px;padding-right:5px;display:inline-block;}#ssButtonContent{background : url('../img/bg_button.gif?42.27.0')  repeat-x center center;height:32px;text-align:left;padding-left:5px;padding-right:5px;display:inline-block;font-size:10px;}#ssButtonContent2{padding-top:2px;font-weight:bold;white-space:nowrap;}#ssButtonContent3{font-weight:bold;color:#76D6FF;white-space:nowrap;}.ssButtonContent4{font-weight:bold;color:#FD0606;white-space:nowrap;height:32px;text-align:center;vertical-align:middle;padding-top:8px;}#likeThese{display:none;}#likeTheseDiv{width:450px;}.likeTheseHeader{font-weight:bold;}.likeTheseInputWrapper{padding:10px 5px 5px 5px;margin-left:10px;}.likeTheseSaveNoThanksDiv{padding:10px 20px 20px 10px;text-align:right;}#likeTheseDiv div.floatRight{display:none;}#likeTheseDiv .popupHdr{background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x scroll right bottom transparent;}#likeTheseBody{background-color:#FFF;}.arHeadline{margin-left:5px;direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.arArticle{text-align:right;}.ararticleParagraph{direction:rtl;unicode-bidi:embed;text-align:right;}.arLeadField{text-align:right;}.arArticle table{width:100%;}#headlineTabs.selectedTabAll #articleViewAs{display:none;}a, a:hover,.headline a,.headline a:hover,.headline a:active,.headline a:visited {text-decoration:none;color:#000;cursor:text;}#contentWrapper {border:none;background:none;}img,input, select,#menubarleft,#menubarright,#navcontainer ul,#breadtrail,#postProcessingNav,.content-header a,.industryReportHeader a {visibility:hidden;display:none;}#navcontainer {margin:40px 10px 0 10px;padding:0px 10px 0 10px;border-bottom:solid 1px #DEDEE9;}#navcontainer h1 {margin:0;padding:0;font-size:24px;font-weight:normal;}#navcontainer .djrlogo {visibility:visible;}#snapshotHeader {border:none;}#headlineFrame, #carryOver {padding-left:10px;}.article {page-break-after:always;}#lastArticle {page-break-after:auto;}html>body #lastArticle {page-break-after:avoid;}</style>

</head>
<body class=''><div id="navcontainer" class="fcpNavContainer">
<table cellpadding="0" cellspacing="0" border="0" width="100%">
<tr>
<td class="factivalogo"><h1>Factiva</h1></td>
<td class="djrlogo" align="right"><span>Dow Jones</span></td>
</tr>
</table>
</div>
<form name="PageBaseForm" method="post" action="/aa/default.aspx?pp=Save&amp;hc=Publication" id="PageBaseForm">
<div>
<input type="hidden" name="_XFORMSESSSTATE" id="_XFORMSESSSTATE" value="AB57MDp7MTU5Ons4OiJtYm0wLTAiLDA6MCwyOiJTIiwzOlsiMTQ2Il0sNDoiZW4iLDWABQJ1YWxidLwEDTE6MSwyOjAsMzoiMkNBTiJgBQZhbm5hLm1haEB8BARlcnRhLmNhaAcPIjE2Iiw2OnswOns0OiIwMDg2bAgNImNvZXhlLDAsMDtjb3RyboQBAA1lbnR3c2pwLDI7Y29jdXMsMCIsMToiZHRtb24sMCJ9cAEAFjgyMjIwNEY2ODAwMkE0MDA3MjEyNDY0MkJERDY4NUUwMjQwRTgwMHxqAHwwMQQAAy0xIn0sN5gRBzEyOiJBbGwiLDGdATFcCwsyNiwyOjF9LDg6MCwxMIUce3gAwR59jBADRjA4QzIwfAwPODAyNjAwMUJDfDAyMTAwMTEwKQMAMjEydQEzcAAFMDAxMDAzMDKgEgYifX0sNjowLDe0LwAHIn0sVToiL2FhL2RlZmF1bHQuYXNweCJ9fREAAKcBAAA=" />
<input type="hidden" name="_XFORMSTATE" id="_XFORMSTATE" value="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" />
<input type="hidden" name="__VIEWSTATE" id="
__VIEWSTATE" value="" />
</div>
<div id="contentWrapper"><div id="contentLeft"><span></span><div  class="article enArticle"><p>
<div>
Technology & Health
</div>
<div id="hd" ><b class='enHeadline'>
Gene-Therapy Trials,
AIDS Study on Twins
Are Cleared by NIH
</b>
</div><div>231 words</div><div>7 October 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B3</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
WASHINGTON -- The National Institutes of Health has approved two
genetherapy trials for treating cancer and an AIDS study that it
says could pave the way for future gene therapies.
</p>
<p class="articleParagraph enarticleParagraph">
Genetic Therapy Inc. said it won NIH approval to insert into
cancerous cells of certain lung-cancer patients a gene that has the
potential to slow the growth rate of tumor cells.
</p>
<p class="articleParagraph enarticleParagraph">
The Gaithersburg, Md., concern also said it received permission
to transfer Interleukin-4 (IL-4), a protein that causes immune cells
to grow, into certain cancer patients' tumor cells. The object is to
improve the response of the body's natural immune system to cancer
cells.
</p>
<p class="articleParagraph enarticleParagraph">
Both trials also need approval from the Food and Drug
Administration.
</p>
<p class="articleParagraph enarticleParagraph">
The NIH's recombinant DNA advisory committee also approved an
AIDS study involving identical twins. Specifically, it authorized
NIH scientists to study the safety and survival of genetically
tagged white blood cells in sets of twins where one twin is infected
with the human immunodeficiency virus (HIV) and one isn't.
</p>
<p class="articleParagraph enarticleParagraph">
According to the Journal of the National Cancer Institute, the
scientists will remove white blood cells from uninfected twins, tag
them with a bacterial neomycin resistance gene, then infuse them
into the HIV-positive twins. The scientists then will track the
cells to see how long they survive.
</p>
<p>Document j000000020011107doa700p1f</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Who's News
</div>
<div id="hd" ><b class='enHeadline'>
Genetic Therapy Inc.
</b>
</div><div>62 words</div><div>3 September 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B2</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
GENETIC THERAPY Inc. (Gaithersburg, Md.) -- Robert C. Riley, 38
years old, was named to the new position of senior vice president,
business development and planning, for this maker of human gene
therapy products for the treatment of genetic and other diseases. He
had been senior director of business development and planning at
Bristol-Myers Squibb Co.
</p>
<p>Document j000000020011107do9300lqy</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology & Health
</div>
<div id="hd" ><b class='enHeadline'>
AIDS Conference to Unleash Research
Covering Vaccines and Gene Therapy
</b>
</div><div class="author">
By Marilyn Chase
</div><div>Staff Reporter of The Wall Street Journal</div>
<div>728 words</div><div>15 July 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B4</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
The Eighth International Conference on AIDS, opening
Sunday in Amsterdam, will unleash a wave of research
including new strategies involving vaccines and gene therapy.
</p>
<p class="articleParagraph enarticleParagraph">
About 9,000 scientists, activists and reporters will piece
together a mosaic of the global epidemic from 4,875 reports
that will be presented on everything from how AIDS is
spreading in the developing world to women's vulnerability to
the AIDS virus. Politically, activist groups are gearing up
to renew their attacks on drug companies over testing and
pricing policies.
</p>
<p class="articleParagraph enarticleParagraph">
The U.S. Centers for Disease Control will present a report
on two Thai strains of the AIDS virus. One strain is spread
by using dirty needles, while the other is spread through
sex, especially heterosexual contact in Thailand's bars and
brothels.
</p>
<p class="articleParagraph enarticleParagraph">
"In northern Thailand, there is the fastest spread of an
AIDS virus that anyone's ever seen," says Max Essex, a
Harvard University AIDS researcher who is the conference's
co-chairman for science. The outbreak raises questions about
whether the virus can evolve in a way that hastens
heterosexual transmission.
</p>
<p class="articleParagraph enarticleParagraph">
Conference participants say issues involving women and
AIDS will get some overdue attention. Recent reports have
shown that women have additional symptoms, less access to
experimental drugs and swifter death from the disease than do
men. Health officials are wrestling over an updated
definition of AIDS that would include certain infections and
cancers of the female reproductive tract. Delay of the new
definition means many women lack a formal diagnosis, and
therefore can't get insurance or disablity coverage.
</p>
<p class="articleParagraph enarticleParagraph">
One of the most eagerly awaited vaccine reports will come
from a team led by Robert Redfield at Walter Reed Army
Medical Center in Washington. Dr. Redfield has been testing
vaccines as a type of immune therapy in people who already
are infected with the AIDS virus. This spring he forecast
that his data will show the treatments lower virus levels and
stabilize infection-fighting immune cells.
</p>
<p class="articleParagraph enarticleParagraph">
"Everyone has been waiting for six months for Redfield to
decode his results," Dr. Essex said. "My hope is that he'll
be presenting new data on that."
</p>
<p class="articleParagraph enarticleParagraph">
A number of groups are tinkering with the AIDS virus's
genetic code, removing its most virulent genes, or splicing
in new genes that somehow curtail its lethal life cycle. Zene
Matsuda of Harvard will present his strategy using a gene
called X, found in simian AIDS. When patched into human
immunodeficiency virus, "it dramatically inhibits the ability
of HIV to replicate," Dr. Essex said.
</p>
<p class="articleParagraph enarticleParagraph">
A second gene-therapy strategy involves implanting a
genetic "booby trap" within the AIDS virus. David Klatzmann
of Hopital de la Pitie-Salpetriere in Paris stitched into HIV
a gene borrowed from herpes virus. That gene, called TK,
renders herpes vulnerable to the common drug acyclovir. When
the AIDS virus implanted with the gene tries to replicate,
and researchers treat it with acyclovir, it self destructs.
</p>
<p class="articleParagraph enarticleParagraph">
AIDS activists attending the international meeting of
researchers and health officials are gearing up to renew
their attacks on several pharmaceutical companies over their
drug testing and pricing policies. This year's prime target:
Abbott Laboratories of Abbott Park, Ill., for delaying the
start of a test to determine whether its HIVIG product can
block transmission from pregnant AIDS patients to their
fetuses. Abbott has defended the delay as necessary to secure
an unusual product liability waiver from the National
Institutes of Health.
</p>
<p class="articleParagraph enarticleParagraph">
Activists may take aim at a second company, Astra
Pharmaceutical Products Inc., for charging more than $20,000
a year for foscarnet, its drug to treat AIDS-related
blindness. Astra Pharmaceutical, based in Westborough, Mass.,
is a unit of AB Astra of Sweden.
</p>
<p class="articleParagraph enarticleParagraph">
A San Francisco AIDS activist, Jim Driscoll, predicted
that scholarly presentations won't be disrupted, but he said
activists may try to shut down the corporate trade show
displays.
</p>
<p class="articleParagraph enarticleParagraph">
Originally planned for Boston, the 1992 conference was
moved abroad to protest the Bush administration's ban on
immigrants who carry the AIDS virus. "We made a decision --
and it was an easy consensus -- that we couldn't hold a
meeting in a country with immigration restrictions," said
Paul Volberding, director of San Francisco General Hospital's
AIDS program and head of the International AIDS Society.
</p>
<p>Document j000000020011107do7f00gz9</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>
Technology Brief -- Genetic Therapy Inc.:
Trials for Cancer Treatments
Gain Approval by the NIH
</b>
</div><div>147 words</div><div>4 June 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B6</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
Genetic Therapy Inc. said the National Institutes of
Health approved two gene therapy trials and two gene transfer
trials for treatment of cancer.
</p>
<p class="articleParagraph enarticleParagraph">
One gene therapy trial, for the treatment of primary brain
tumors, is designed to induce cancerous cells to produce an
enzyme that makes tumors susceptible to the approved
anti-viral drug ganciclovir, the Gaithersburg, Md.,
biotechnology concern said.
</p>
<p class="articleParagraph enarticleParagraph">
The NIH also approved a gene therapy trial involving the
use of Interleukin-2, which induces immune cell growth in the
treatment of neuroblastoma, the most common form of solid
tumors in children, the company said.
</p>
<p class="articleParagraph enarticleParagraph">
The two gene transfer trials will assess results of bone
marrow transplants in patients with leukemia, multiple
myeloma and breast cancer.
</p>
<p class="articleParagraph enarticleParagraph">
The trials will begin after approval by the Food and Drug
Administration, the company said.
</p>
<p>Document j000000020011107do6400dhd</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>
Technology Brief -- Genetic Therapy Inc.:
Firm Signs Licensing Pact
With University of Texas
</b>
</div><div>160 words</div><div>30 April 1992</div><div>The Wall Street Journal</div><div>J</div><div>NO PAGE CITATION</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
GAITHERSBURG, Md. -- Genetic Therapy Inc. said it signed a
licensing agreement with the University of Texas to develop
gene-based products to treat high blood cholesterol.
</p>
<p class="articleParagraph enarticleParagraph">
Under the agreement, the biotechnology company obtains the
right to use the gene for the low density lipoprotein
receptor in human gene therapy from the university's
Southwestern Medical Center in Dallas. The non-exclusive
license allows Genetic Therapy to use the receptor for low
density lipoprotein, or LDL, to develop gene-based therapies
for high cholesterol levels and coronary artery disease.
</p>
<p class="articleParagraph enarticleParagraph">
The agreement calls for the company to make up-front and
royalty payments to the university. The patents covered by
the license were awarded to three researchers at the
university, Drs. Michael S. Brown, Joseph L. Goldstein and
David W. Russell. Drs. Brown and Goldstein jointly received
the 1985 Nobel Prize for physiology for their research in
cholesterol metabolism.
</p>
<p>Document j000000020011107do4u00a88</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology
</div>
<div id="hd" ><b class='enHeadline'>
Cistron Biotechnology,
Genetic Therapy Set
Pact on Interleukin
</b>
</div><div>237 words</div><div>1 April 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE C20</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
GAITHERSBURG, Md. -- Genetic Therapy Inc. reached an
agreement with Cistron Biotechnology Inc. to develop and sell
cancer treatments from Cistron's experimental substance
interleukin-1 beta.
</p>
<p class="articleParagraph enarticleParagraph">
Under the agreement, Genetic Therapy will pay Cistron an
undisclosed sum plus royalties from the sales of the products
developed. The companies declined to disclose financial terms
of the agreement.
</p>
<p class="articleParagraph enarticleParagraph">
Interleukin, a natural protein produced through
gene-splicing technology, causes cells of the immune system
to grow and is thought to bolster the body's defense against
disease, including cancer. Genetic Therapy, which develops
delivery systems for gene therapy, said this is the first
gene related to cancer for which it has exclusive rights. The
company has exclusive rights to one other gene, which is
related to hemophilia.
</p>
<p class="articleParagraph enarticleParagraph">
Cistron originally had a marketing agreement with Du Pont
Co. and a joint venture between Du Pont and Merck & Co.,
giving the two companies all rights over sales of therapeutic
products from interleukin-1 beta. But the two companies last
August returned the rights to Cistron, leaving it to seek
partnerships with other companies. Cistron said interleukin-1
beta also has potential uses in the treatment of such
autoimmune diseases as arthritis and systemic lupus. Cistron
currently makes interleukin-1 beta test kits, which are used
in research and which account for all of the company's $1.2
million in annual sales.
</p>
<p>Document j000000020011107do41007bp</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Who's News
</div>
<div id="hd" ><b class='enHeadline'>
Genetic Therapy Inc.
</b>
</div><div>83 words</div><div>28 February 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B5</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
GENETIC THERAPY Inc. (Gaithersburg, Md.) -- Jacques F.
Rejeange, 51 years old, was named a director of this human
gene therapy research and development firm. Mr. Rejeange is
president and chief executive of Sandoz Pharmaceuticals
Corp., East Hanover, N.J., a unit of Sandoz AG, the Swiss
pharmaceutical concern. His appointment increases the board
to nine members. Sandoz and Genetic Therapy entered into a
collaborative agreement in 1991 that entitled Sandoz to one
member on Genetic's board.
</p>
<p>Document j000000020011107do2s0044b</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology & Health
</div>
<div id="hd" ><b class='enHeadline'>
Gene Therapy Test
In AIDS May Begin
Within Months
</b>
</div><div class="author">
By Marilyn Chase
</div><div>Staff Reporter of The Wall Street Journal</div>
<div>519 words</div><div>14 February 1992</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B2</div><div>English</div><div>
(Copyright (c) 1992, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
The first tentative test of gene therapy in acquired
immune deficiency syndrome could get under way within a
couple of months.
</p>
<p class="articleParagraph enarticleParagraph">
The experiment, which received federal approval this week,
is a collaboration between scientists from a unit of Immunex
Corp. and the Fred Hutchinson Cancer Research Center in
Seattle.
</p>
<p class="articleParagraph enarticleParagraph">
Scientists envision treating between five and 15 AIDS
patients who also are suffering from an AIDS-linked
malignancy, B-cell lymphoma. They will be patients slated to
undergo a bone-marrow transplant for the treatment of their
cancer, and shortly after that procedure doctors plan to
insert special genetically altered cells to treat the virus.
</p>
<p class="articleParagraph enarticleParagraph">
A test of the new treatment got a green light by the
National Institutes of Health Recombinant DNA Advisory
Committee, after gaining approval of the U.S. Food and Drug
Administration in January.
</p>
<p class="articleParagraph enarticleParagraph">
The aim of the experiment is to flood the body of these
patients with huge numbers of killer T-cells, which are
specifically targeted immune cells that attack and kill
AIDS-infected cells. In case the experiment should go awry or
provoke toxic side effects, the killer cells will be equipped
with a gene that acts as a so-called suicide switch, enabling
doctors to turn off the experiment simply by giving the
patients an antibiotic.
</p>
<p class="articleParagraph enarticleParagraph">
The suicide gene is to be spliced into the killer cells
using classical genetic engineering techniques. Such
techniques employ a mouse-tumor virus as a tool to insert a
gene rendering the cells sensitive to the antibiotic
ganciclovir. Once inserted, this gene acts as a switch
scientists can use to inactivate the killer cells, and turn
off the experiment at will, with a dose of ganciclovir.
</p>
<p class="articleParagraph enarticleParagraph">
Treating immune-suppressed patients with one billion
virus-fighting cells is a delicate procedure, with some risk
the immune reaction might become "over-exuberant," explained
team leader Philip A. Greenberg of the Hutchinson Center.
</p>
<p class="articleParagraph enarticleParagraph">
"We're trying to rebuild an enormous immune response in
these patients," said Dr. Greenberg in an interview. "But
there's the potential that the immune response might be too
strong, and might cause inflammation to the brain and lung.
The suicide switch really broadens the safety margin of the
experiment."
</p>
<p class="articleParagraph enarticleParagraph">
So far, American scientists have used gene therapy in
several separate tests to treat cancer patients and children
with a hereditary immune weakness known as ADA deficiency.
Those experiments have been led by Drs. Steven A. Rosenberg
and W. French Anderson at the National Institutes of Health.
A third gene therapy treatment for patients with hereditary
high cholesterol has been approved by NIH to take place at
the University of Michigan.
</p>
<p class="articleParagraph enarticleParagraph">
One gene therapy pioneer, Dr. Anderson of NIH, called the
Seattle experiment "very exciting . . . a very important
protocol."
</p>
<p class="articleParagraph enarticleParagraph">
In a related move, Immunex announced plans to spin off its
Targeted Genetics Corp. unit to pursue gene therapy as an
independent company. Following a planned private placement of
stock, the biotech firm said it will retain a 40% stake in
the new company.
</p>
<p>Document j000000020011108do2e001e0</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology
</div>
<div id="hd" ><b class='enHeadline'>
Genetic Therapy Inc.
Enters Into Ventures
With Unit of Sandoz
</b>
</div><div>239 words</div><div>26 November 1991</div><div>The Wall Street Journal</div><div>J</div><div>NO PAGE CITATION</div><div>English</div><div>
(Copyright (c) 1991, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
GAITHERSBURG, Md. -- Genetic Therapy Inc. said it entered
a broad series of collaborative agreements with a unit of
Sandoz Ltd. of Switzerland to develop and commercialize
gene-transfer technology.
</p>
<p class="articleParagraph enarticleParagraph">
The Sandoz unit, Sandoz Pharma Ltd., in a related move,
purchased 470,357 Genetic Therapy common shares for $10
million, or $21.26 a share. The shares represent a 6.1% stake
and will entitle Sandoz to nominate one director to Genetic
Therapy's board. Currently, there are eight directors on the
board.
</p>
<p class="articleParagraph enarticleParagraph">
After the announcement yesterday, Genetic Therapy rose
87.5 cents to $13.875 in national over-the-counter trading.
</p>
<p class="articleParagraph enarticleParagraph">
Genetic Therapy said Sandoz Pharma agreed to provide as
much as $13.5 million over three years for as many as three
projects; Genetic Therapy itself would contribute $1 million
a project. Sandoz Pharma also agreed to provide milestone
payments of as much as $11.5 million a product "upon the
occurrence of certain events," Genetic Therapy said. The
collaborative effort covers applications in immunology/
inflammation, including asthma; cancer; and cardiovascular
disease.
</p>
<p class="articleParagraph enarticleParagraph">
In turn, Genetic Therapy said it granted Sandoz Pharma the
exclusive world-wide right to use technology developed under
the agreement and to make and sell related products in
exchange for royalties. Genetic Therapy noted the pact
doesn't apply to certain research areas, including genetic
diseases, where Genetic Therapy intends to develop products
itself.
</p>
<p>Document j000000020011109dnbq00tz0</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>
Medicine:
Gene Therapy
To Be Tested
In Cancer Cases
</b>
</div><div class="author">
By Marilyn Chase
</div><div>Staff Reporter of The Wall Street Journal</div>
<div>920 words</div><div>14 November 1990</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B1</div><div>English</div><div>
(Copyright (c) 1990, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
After running a long gantlet of regulatory review, the
first real test of human gene therapy for cancer got final
approval from the Food and Drug Administration and could
proceed in a matter of weeks.
</p>
<p class="articleParagraph enarticleParagraph">
A team of scientists led by Steven A. Rosenberg of the
National Cancer Institute will soon launch the trial in three
patients with a virulent and fatal form of skin cancer. His
chief collaborators are R. Michael Blaese of the cancer
institute and W. French Anderson of the National Heart, Lung
and Blood Institute.
</p>
<p class="articleParagraph enarticleParagraph">
"We're evaluating the first three patients now," Dr.
Rosenberg said. "We'll start with three, and then add one
patient a week" until the study group reaches the approved
maximum of 50, he added. Researchers stressed the regimen
carries no guarantee of success, and isn't without risk.
</p>
<p class="articleParagraph enarticleParagraph">
The test will involve patients with advanced melanoma, a
very aggressive and fatal skin cancer that has spread to
other sites in the body. Candidates for the treatment will be
limited to patients in whom all other treatments have failed,
and who have a life expectancy of months, Dr. Rosenberg said.
</p>
<p class="articleParagraph enarticleParagraph">
"Melanoma is the most rapidly increasing form of cancer in
the United States," he noted. "People have related it to
increased sun exposure, but there are clearly other factors
we don't understand." Melanoma will account for 27,600 cases
and 8,800 deaths in 1990 -- a nearly 80% increase since 1973,
according to NCI statistics.
</p>
<p class="articleParagraph enarticleParagraph">
The highly experimental technique involves removing
special cancer-fighting white blood cells, called
tumor-infiltrating lymphocytes, or TILs. Researchers will
insert a gene that makes a cancer-fighting substance, tumor
necrosis factor (TNF). Then the cells are bathed in growth
factors and reinfused into the patient to deliver their
lethal payload right into the tumor.
</p>
<p class="articleParagraph enarticleParagraph">
The move to real gene therapy was preceded by a sort of
dress rehearsal in which cancer patients received TIL cells
endowed with a special marker gene that allowed researchers
to track their progress as they homed in on the tumor.
</p>
<p class="articleParagraph enarticleParagraph">
The TNF gene is inserted into the human cells by using an
animal tumor virus, Moloney mouse leukemia virus. (Viruses
are the delivery-vehicle of choice in genetic engineering
because they work by wriggling into the DNA of their target.)
The virus isn't known to cause disease in humans, but its use
did arouse some controversy, even though it will be crippled
to prevent it from surviving after it deposits the gene in
the cell.
</p>
<p class="articleParagraph enarticleParagraph">
TNF, a natural substance believed to block a tumor's blood
supply, has proved effective in treating cancer in mice. So
far, however, tests of TNF in people have failed. Dr.
Rosenberg reasons that this is because mice can tolerate up
to 40 times as much TNF as humans. He theorizes that "it
takes that 40-fold difference to cause the anti-tumor
effects." TNF can cause serious side effects including shock
and body wasting, but targeting the agent is hoped to mute
this risk.
</p>
<p class="articleParagraph enarticleParagraph">
"With TIL cells making large amounts of TNF, we can
concentrate it at the tumor site," said Dr. Rosenberg. "This
gene therapy is a way to expose the tumor to high amounts of
TNF without exposing the rest of the body." The technique
underwent safety tests in six rhesus monkeys and was judged
safe to administer.
</p>
<p class="articleParagraph enarticleParagraph">
The plan is to give the patients massive doses of the TIL
cells armed with their new gene, beginning with three billion
cells and roughly tripling that volume every three weeks up
to a maximum dose of 300 billion cells.
</p>
<p class="articleParagraph enarticleParagraph">
Dr. Rosenberg emphasized there is no guarantee of
therapeutic benefit to the patients who volunteer for the
study.
</p>
<p class="articleParagraph enarticleParagraph">
"This is a highly experimental technique, and one of the
first applications of gene therapy to treat human disease,"
he said. As reported, a trial led by Drs. Blaese and Anderson
earlier this year inserted a gene to correct an enzyme
deficiency in children with an inborn immune deficiency. That
disease, called ADA defiency, was made famous by the plight
of a boy in Texas who lived out his brief life in an
antiseptic plastic "bubble."
</p>
<p class="articleParagraph enarticleParagraph">
"As to whether this {cancer} treatment will have an
impact, I can't say," Dr. Rosenberg said. "But I'm hopeful
the approach will have promise." Because his office is
receiving 25 to 30 calls a day from would-be volunteers, he
said, "It's important to emphasize that it's a very limited
study."
</p>
<p class="articleParagraph enarticleParagraph">
Dr. Rosenberg's quest to "change the genetic makeup of
individuals, as opposed to applying external treatment" began
more than two decades ago when he witnessed a rare
spontaneous cancer remission in a patient during his surgical
residency in Boston. That sparked an interest in
immunotherapy, in which the body's own immune defenses are
marshaled to help fight cancer.
</p>
<p class="articleParagraph enarticleParagraph">
He has long worked on honing an approach that combines TIL
cells, beefed up in a bath of the growth factor interleukin-2
(IL-2), a combination that has shrunk tumors in a fraction of
terminal kidney cancer and melanoma patients. Despite
headlines that heralded the approach five years ago as a
breakthrough, the technique to date has produced only a
handful of lasting, complete remissions.
</p>
<p class="articleParagraph enarticleParagraph">
Introducing real gene therapy into this arsenal, while
exciting, "is by no means the culmination," Dr. Rosenberg
said yesterday. "It is another step in an ongoing scientific
investigation."
</p>
<p>Document j000000020011115dmbe00se8</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology & Medicine
</div>
<div id="hd" ><b class='enHeadline'>
First Human-Gene Therapy
Begins for ADA Deficiency
</b>
</div><div>269 words</div><div>17 September 1990</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B4C</div><div>English</div><div>
(Copyright (c) 1990, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
BETHESDA, Md. -- Scientists at the National Institutes of
Health began the first human-gene therapy experiment, taking
a step that many hope will change the face of medicine.
</p>
<p class="articleParagraph enarticleParagraph">
A four-year-old girl suffering from a genetic disorder
called ADA deficiency, a rare and devastating malfunction of
the immune system, was given an infusion of cells containing
copies of a gene she lacks. She is missing the ADA gene,
which manufactures an enzyme that clears wastes from the
body. Scientists hope the adenosine deaminase genes they have
inserted into the unidentified girl's bloodstream will begin
producing the missing enzyme and rebuild her immune system.
</p>
<p class="articleParagraph enarticleParagraph">
It will be several months before the doctors, French
Anderson of the National Heart, Lung and Blood Institute, and
Michael Blaese and Kenneth Culver of the National Cancer
Institute, know whether, or how well, the experiment works.
But the initial infusion went well, scientists and the girl's
father said.
</p>
<p class="articleParagraph enarticleParagraph">
The doctors will monitor the patient, as well as several
other children who will have similar infusions later, to
learn how long the cells containing copies of the ADA gene
will survive in the girl's bloodstream and how much her
immune system improves.
</p>
<p class="articleParagraph enarticleParagraph">
An NIH panel cleared the path-breaking therapy in late
July after lengthy review and the Food and Drug
Administration gave its approval just hours before the
infusion Friday.
</p>
<p class="articleParagraph enarticleParagraph">
Gene therapy may ultimately help treat or cure a wide
range of diseases and disorders, including cancer, cystic
fibrosis, sickle cell anemia, certain types of arthritis and
some mental disorders.
</p>
<p>Document j000000020011115dm9h00mz5</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>
NIH Panel Clears First Human Tests of Gene Therapy
</b>
</div><div class="author">
By Kenneth H. Bacon
</div><div>Staff Reporter of The Wall Street Journal</div>
<div>1066 words</div><div>1 August 1990</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B1</div><div>English</div><div>
(Copyright (c) 1990, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
BETHESDA, Md. -- A National Institutes of Health panel
opened a new frontier in medicine by approving the first
human tests of gene therapy to fight disease.
</p>
<p class="articleParagraph enarticleParagraph">
One experiment cleared by the panel will enable NIH
doctors to implant genes designed to enhance the body's
ability to fight metastatic melanoma, a fatal skin cancer.
The second experiment will test the use of gene implants to
treat ADA deficiency, a rare and congenital immune-system
defect.
</p>
<p class="articleParagraph enarticleParagraph">
In recent years, scientists have traced a number of
inherited disorders, such as ADA deficiency, hemophilia and
cystic fibrosis, to specific malfunctions by genes, which
instruct cells to perform various tasks. At the same time,
researchers are concluding that diseases such as cancer,
diabetes, heart disease and some manic-depressive illnesses
partly result from genetic malfunctions. Thus, scientists
have begun to focus on therapies to replace missing genes or
to enhance the performance of existing genes as a possible
key to treating many diseases and disorders.
</p>
<p class="articleParagraph enarticleParagraph">
Scientists believe that gene therapy will eventually
graduate from the laboratory to medical practice and emerge
as a common method of treating a wide range of diseases and
disorders. "In the next 20 years, we may be able to treat
some of the more common genetic diseases with gene therapy,"
predicted Robert Murray of the division of medical genetics
at Howard University in Washington. He said there would be
strong medical and commercial benefits in developing a gene
therapy for fairly widespread genetic defects, such as
sickle-cell anemia, which afflicts about 50,000 American
blacks. He also said the gene therapy eventually may treat
certain types of high blood pressure.
</p>
<p class="articleParagraph enarticleParagraph">
Yesterday's approvals move gene therapy "from abstract
science to research and patient care," said Gerard McGarrity,
chairman of the Recombinant DNA Advisory Committee, the NIH
panel that cleared the tests. "The field of medicine has been
looking for this kind of therapy for a thousand years," he
said, calling the panel's votes "an historic moment."
</p>
<p class="articleParagraph enarticleParagraph">
"Unfortunately, we don't know exactly what the
ramifications are," warned Mr. McGarrity, who is the
president of the Coriell Institute for Medical Research in
Camden, N.J. "Nobody can say where this is going in the
future or how many applications we'll see."
</p>
<p class="articleParagraph enarticleParagraph">
Scientists don't know for sure how -- or even whether --
human gene implants will work, much less the risks of trying
to fine-tune the body's genetic mechanism. Moreover, gene
therapy has attracted criticism from groups that worry it
could lead to pressure to tinker with genetic structures in
order to improve the human race.
</p>
<p class="articleParagraph enarticleParagraph">
For these reasons, the NIH has put the proposals through a
rigorous review process. The Recombinant DNA Advisory
Committee, a group of scientists, ethicists and lawyers, is
the last major hurdle. The Food and Drug Administration and
the acting director of NIH must still sign off on the
proposed experiments, but their approval is considered a
certainty.
</p>
<p class="articleParagraph enarticleParagraph">
In both experiments, scientists will remove immune-system
cells from patients and grow large amounts of these cells,
called lymphocytes, in the laboratory. Then they will splice
specific genes into the cells and infuse them into the
patient. The cancer therapy will add a gene for
tumor-necrosis factor (TNF), a protein that destroys tumor
cells. The ADA therapy will add a gene responsible for the
enzyme adenosine deaminase (ADA). Victims of the disorder
lack ADA, which is responsible for clearing wastes from the
body.
</p>
<p class="articleParagraph enarticleParagraph">
The tests will start in the fall on small numbers of NIH
patients who consent to take part in the experiments, which
draw heavily on gene-implant research done by French Anderson
of NIH's Heart, Lung and Blood Institute. It may be some time
before scientists know how safe the therapies are and how
well they work.
</p>
<p class="articleParagraph enarticleParagraph">
The advisory panel authorized Dr. Anderson and two NIH
colleagues, Michael Blaese and Kenneth Culver, to start the
ADA therapy on as many as 10 children. The review process,
which took almost a year, was complicated by the fact that
all the test subjects will be children. In addition, there
are already two therapies available for patients with ADA
deficiency: bone marrow transplants, which only work for a
minority of the fewer than 10 children born each year in the
U.S. with the disorder; and the drug PEG-ADA, a treatment
developed about five years ago that improves immune response
in most patients. The researchers will administer the ADA
gene therapy along with PEG-ADA.
</p>
<p class="articleParagraph enarticleParagraph">
Even though ADA deficiency is rare, it received wide
publicity several years ago from television reports of a
Texas boy who had to live in a plastic bubble to protect him
from infection and who subsequently died. Most victims of ADA
deficiency die from respiratory diseases in their youth.
</p>
<p class="articleParagraph enarticleParagraph">
The panel authorized Steven Rosenberg of the National
Cancer Institute to test the safety of TNF therapy on as many
as 50 volunteers. In an unusual move, the panel approved Dr.
Rosenberg's proposal the first time he presented it. Members
of the panel said the quick approval came because Dr.
Rosenberg is dealing with terminally ill patients for whom
there is no therapy. In addition, Dr. Rosenberg, who has won
committee approval for two other experimental cancer
therapies, did an effective job of using new data from tests
with monkeys to address safety concerns.
</p>
<p class="articleParagraph enarticleParagraph">
Monday, Dr. Rosenberg told the panel's Human Gene Therapy
Subcommittee that TNF has "almost been miraculous in what it
can do" in reducing tumors in mice. "Within 15 to 30 minutes
we can see necrosis and the dissolution of tumors." However,
he said that "TNF administration to humans has been an
abysmal failure" when attempted in a solution injected
intravenously.
</p>
<p class="articleParagraph enarticleParagraph">
Now Dr. Rosenberg will insert TNF into tumor-infiltrating
lymphocytes, especially grown and strengthened cells that are
designed to zero in on cancers in the body. He hopes that the
combination will produce a promising therapy.
</p>
<p class="articleParagraph enarticleParagraph">
When administered in some earlier applications, TNF has
caused the body to begin wasting away. Dr. Rosenberg hopes
that the more targeted application will be less risky. The
point of his initial tests will be to test the human
tolerance and safety of TNF gene therapy when administered in
connection with interleukin-2, a protein made by Cetus Corp.
</p>
<p>Document j000000020011115dm8100j2w</p></div><br/><span></span><div  class="article enArticle"><p>
<div>
Technology & Medicine
</div>
<div id="hd" ><b class='enHeadline'>
AIDS Scientists Discuss Latest Findings
---
Subjects Range From
Vaccines to Gene Therapy
</b>
</div><div class="author">
By Marilyn Chase
</div><div>Staff Reporter of The Wall Street Journal</div>
<div>1515 words</div><div>17 April 1990</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B4</div><div>English</div><div>
(Copyright (c) 1990, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
KEYSTONE, Colo. -- While the field of AIDS research boasts
few breakthroughs these days, scientists at a meeting here
heard a report about a provocative French vaccine test, plus
a variety of new insights into treating the epidemic.
</p>
<p class="articleParagraph enarticleParagraph">
The reports inspired hope that researchers might be able
to avoid the use of dangerous killed-virus vaccines, to find
ways to block transmission of the virus by pregnant women and
to evade the problems of toxicity and resistance to the drug
AZT. New treatment strategies, including gene therapy and
immunotherapy, also got a hearing.
</p>
<p class="articleParagraph enarticleParagraph">
The weeklong meeting earlier this month, one in a series
of annual winter symposiums held by the University of
California at Los Angeles, drew about 750 participants to
this Rocky Mountain site.
</p>
<p class="articleParagraph enarticleParagraph">
From the Pasteur Institute in Paris came word of what may
be the first protein-based vaccine to protect a chimpanzee
against infection by the virus that causes acquired immune
deficiency syndrome. If confirmed, it will be the first time
an animal has been shielded from infection without resorting
to a killed-virus vaccine. While a success in animal tests,
killed-virus vaccines still strike many researchers as too
risky to use in uninfected humans.
</p>
<p class="articleParagraph enarticleParagraph">
Marc Girard, a vaccine researcher at Pasteur, reported
preliminary success in a test of two chimpanzees vaccinated
with "cocktails" of synthetic protein fragments. These
cocktails, though different, included a key ingredient in
common: a synthetic protein fragment that copies a part of
the AIDS virus's outer coat that scientists think could spark
a potent immune response. It's called the "V3 loop."
</p>
<p class="articleParagraph enarticleParagraph">
Both vaccinated animals were then exposed to live AIDS
virus. Six months later, both chimps appear to be free of
infection, according to a lymph node biopsy and PCR
gene-amplification techniques. "Whether protection against
infection was achieved, however, will not be known until the
animals have been monitored at least one year," Dr. Girard's
report cautions.
</p>
<p class="articleParagraph enarticleParagraph">
"It's great," responded Jorg Eichberg, an animal vaccine
researcher at the Southwest Foundation for Biomedical
Research in San Antonio, Texas. "Unfortunately, (the
Pasteur's approach) is a little bit of a hodgepodge since the
animals got different things." In addition to the piece of
the V3 loop, one animal got a shot of killed virus, while the
other animal's vaccine was supplemented by other viral
proteins. Also, he noted, the control animals, which became
infected, were tested at different times.
</p>
<p class="articleParagraph enarticleParagraph">
The next challenge will be to unravel which ingredients in
the immunizing cocktail were responsible for protecting the
animals -- a major puzzle that obscures the meaning of the
experiment for now. "But it doesn't detract from his
success," Dr. Eichberg said.
</p>
<p class="articleParagraph enarticleParagraph">
Wade Parks of the University of Miami said 33% of the
babies born to infected mothers carry the AIDS virus. He and
others are conducting a test of AZT in pregnant women. Other
researchers noted that all pregnant women may not be equally
infectious -- an insight that could lead to a different kind
of treatment.
</p>
<p class="articleParagraph enarticleParagraph">
Hans Wigzell of the Karolinska Institute in Stockholm said
his studies of pregnant women infected with the AIDS virus
disclose that those women with the highest levels of certain
antibodies against the "loop" portion of the virus's coat
tend not to transmit the infection to their babies.
</p>
<p class="articleParagraph enarticleParagraph">
Dr. Wigzell said he is laying the foundation for a program
to give passive immunization -- that is, infusions of
antibodies -- to expectant mothers. Dr. Wigzell added he
planned to discuss the approach with officials of the World
Health Organization. "The problem is that you probably need
(large amounts) of immunoglobulin-G," an expensive antibody
infusion, to shield the growing fetus until delivery, he
said.
</p>
<p class="articleParagraph enarticleParagraph">
Several studies shed new light on the uses and problems of
the drug AZT. Douglas D. Richman, who discovered
drug-resistant virus strains in chronic AZT users, said his
group and others have narrowed down the cause of this
resistance to four precise mutations of a single gene that
encodes a viral enzyme, reverse transcriptase. Dr. Richman
said his lab now can screen patients using PCR technology to
detect which ones carry the resistant mutant viruses.
</p>
<p class="articleParagraph enarticleParagraph">
The bad news is that resistance sharply curtails the
drug's usefulness after two years of AZT treatment. The good
news is that resistance doesn't extend to all other drugs in
the AZT family. Also, the new low-dose regimens and early
treatment appear to slow the emergence of drug resistance, he
added.
</p>
<p class="articleParagraph enarticleParagraph">
The theme "less AZT is better" resounded even more
tellingly in the studies of Lawrence Corey of Children's
Hospital of Seattle. Dr. Corey said he stumbled on a
serendipitous finding while conducting a study evaluating
combination therapy of AZT and acyclovir, a herpes drug. The
combination possessed no special synergy, he found. But in a
group of patients with AIDS-related complex, or ARC, he found
the most effective AZT dose wasn't the currently favored 600
milligrams a day, but half that amount.
</p>
<p class="articleParagraph enarticleParagraph">
To prompt a panoply of clinical improvements, including
weight gain, rises in T4 immune cells, reduced symptoms and
lower blood levels of virus, "the most effective dose of AZT
was 300 milligrams a day," he said.
</p>
<p class="articleParagraph enarticleParagraph">
"The minimum effective dose of AZT still isn't known," he
said, admitting that his observation is far from conclusive.
But he said the findings call for a formal study comparing
300 milligrams of AZT with the current 600 milligram regimen.
</p>
<p class="articleParagraph enarticleParagraph">
New strategies against the AIDS-linked cancer, Kaposi's
Sarcoma, or KS, may emerge from studies by Barbara Ensoli and
Robert Gallo of the National Cancer Institute in Bethesda,
Md. Dr. Gallo said his experiments show that KS lesions grow
in response to the protein poured out by an AIDS virus gene
known as TAT. In the test tube, KS growth is inhibited by
adding antibodies to the TAT gene.
</p>
<p class="articleParagraph enarticleParagraph">
Dr. Ensoli added that an anti-serum to certain natural
human growth factors, including interleukin-1 and basic
fibroblast growth factor, also curb growth of KS cells in the
laboratory. Dr. Gallo's team didn't indicate whether such
observations could lead to a practical therapy for the tumor.
Nor did he address his collaboration with a Japanese firm
believed to be developing an experimental treatment for KS.
Dr. Ensoli also declined to comment.
</p>
<p class="articleParagraph enarticleParagraph">
Other groups developing experimental treatments were less
reticent at the Keystone meeting. Gene therapy for AIDS is
being investigated at the laboratory of W. French Anderson at
the National Institutes of Health. Richard Morgan, a member
of the Anderson team, said he is using animal tumor viruses,
stripped of their infectious powers and armed with new genes,
as a means of inducing human cells to produce a potential
host of therapeutic substances. The first such substance to
be spliced is synthetic CD4, a copy of the AIDS virus's
target site on human cells. Because synthetic CD4 can pose as
a decoy, sopping up the virus and sparing human cells, the
Anderson team is testing whether gene therapy could give
humans the ability to produce CD4 or other AIDS drugs.
</p>
<p class="articleParagraph enarticleParagraph">
Robert Redfield of the Walter Reed Army Medical Center,
said he has used a synthetic-protein vaccine made by
MicroGeneSys Inc., West Haven, Conn., to alter the immune
response in five out of eight infected volunteers. Elevated
antibodies and immune cells were detected in the five
responsive volunteers, who also showed less decline in their
T-cells than the three who didn't respond to the treatment.
Dr. Redfield, who is working to assess prospects for eventual
immunotherapy, said the continuing trials show that patients'
immune response can be turned up without toxicity. In a
larger study of 30 patients, he hopes to "refine our
understanding" of immune regulation and disruption in
infected people.
</p>
<p class="articleParagraph enarticleParagraph">
In another test, Joyce Zarling and her co-workers at the
Seattle-based Oncogen unit of Bristol-Myers Squibb Co. said
they are working with a highly toxic protein derived from the
poisonous pokeweed plant. The scientists experimented with
pokeweed antiviral protein, or PAP, and aimed it at human
T-cells (one of the virus's main targets) by fusing it with a
monoclonal antibody. The team reported the protein curbs
virus production by infected cells, but spares 90% of
uninfected cells. Because the toxin is derived from a common
plant, outside observers warned that activists should eschew
home experiments: Consuming pokeweed can cause a
leukemia-like condition that can be fatal.
</p>
<p class="articleParagraph enarticleParagraph">
San Francisco physician Marcus Conant, in collaboration
with a unit of Johnson & Johnson, said a controlled study of
the immune-modulator thymopentin in 90 infected volunteers
slowed the disease process. Dr. Conant said the group
receiving a placebo experienced two cases of AIDS and two
cases of ARC, while the drug group had none. However, to
confirm validity of his findings, he said, "We need a study
in at least 800 patients." Given difficulties in recruiting
study volunteers, he said, that could be hard to do.
</p>
<p>Document j000000020011115dm4h0096q</p></div><br/><span></span><div id="lastArticle"  class="article enArticle"><p>
<div>
Technology & Medicine
</div>
<div id="hd" ><b class='enHeadline'>
Gene Therapy Plan
Set to Be Reviewed
By Bioethical Boards
----
A Wall Street Journal News Roundup
</b>
</div><div>355 words</div><div>19 March 1990</div><div>The Wall Street Journal</div><div>J</div><div>PAGE B2</div><div>English</div><div>
(Copyright (c) 1990, Dow Jones & Co., Inc.)
</div>
</p>
<p class="articleParagraph enarticleParagraph">
Two bioethical boards at the National Institutes of Health
will begin their review today of a proposal to use gene
therapy to treat children with a rare congenital immune
deficiency.
</p>
<p class="articleParagraph enarticleParagraph">
If approved by these boards and other regulatory bodies,
the experiment could become the first authorized therapeutic
gene transplant in the U.S.
</p>
<p class="articleParagraph enarticleParagraph">
The childhood condition, severe combined immune
deficiency, is caused by the lack of the enzyme adenosine
deaminase (ADA), which is responsible for clearing toxic
wastes from the body. The deficiency leaves children
vulnerable to death from overwhelming infection. The
condition was brought to public consciousness several years
ago by the case of a boy in Texas who lived in a protective
plastic bubble.
</p>
<p class="articleParagraph enarticleParagraph">
An NIH team, led by W. French Anderson of the National
Heart, Lung and Blood Institute (NHLBI) and Michael Blaese of
the National Cancer Institute, have proposed a therapeutic
gene transplant in which children with ADA deficiency would
receive a gene to correct the defect. Drs. Anderson and
Blaese couldn't be reached for comment on the review.
</p>
<p class="articleParagraph enarticleParagraph">
Animal experiments show that it is possible to inject mice
and monkeys with a functioning gene that makes the enzyme.
Although no therapeutic gene transfers have ever been
conducted in the U.S., Dr. Anderson and Steven Rosenberg of
the cancer institute successfully inserted a marker gene last
year into special cancer-fighting white blood cells to track
their progress in the body.
</p>
<p class="articleParagraph enarticleParagraph">
This week's hearings are part of a multistage regulatory
review process, which could permit the experiment to take
place as early as this fall. The Institutional Review Board
of the cancer institute, including religious and scientific
figures, is to weigh the proposed experiment today, followed
by a similar board at the NHLBI tomorrow.
</p>
<p class="articleParagraph enarticleParagraph">
If the proposed experiment is approved by the two boards,
it will undergo further hearings at the Recombinant DNA
Advisory Committee of NIH that reviews federally financed
gene-splicing experiments. Approvals from the NIH director
and from the Food and Drug Administration also are required.
</p>
<p>Document j000000020011115dm3j006iq</p></div><br/></div></div><span><div id="pageFooter"><table width="100%" cellspacing="0" cellpadding="0" border="0" class="footerBG">
	<tr>
		<td nowrap="nowrap" width="100%" align="right"><span class="copyright">&copy; 2011 Factiva, Inc.  All rights reserved.</span></td>
		<td><div class="ftright">&nbsp;</div></td>
	</tr>
</table>
<span class='shadowL'></span><span class='shadowR'></span></div></span></form><script type='text/javascript'>framesViewNotReqd = false;modalEnabled = true;modalPopupIframeDefaultSource='/blank.htm';RequestFromModal=false;RequestFromIPad=false;</script>
</body>
</html>